

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Autoimmune Connective Tissue Diseases are Associated with a Risk of Rotator Cuff Repair Surgery

| | |
|-------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2018-023848 |
| Article Type: | Research |
| Date Submitted by the Author: | 27-Apr-2018 |
| Complete List of Authors: | Huang, ShihWei; Shuang Ho Hospital, Physical Medicine and Rehabilitation Lin, CheLi; Taipei Medical University Shuang Ho Hospital, Orthopedics Lin, LiFong; Shuang Ho Hospital, Physical Medicine and Rehabilitation Huang, ChiChang; Graduate Institute of Sports Science, National Taiwan Sport University Liou, Tsan-Hon; Shuang Ho Hospital, Physical Medicine and Rehabilitation Lin, Hui-Wen; Department of Mathematics, Soochow University |
| Keywords: | Rheumatology < INTERNAL MEDICINE, Orthopaedic sports trauma < ORTHOPAEDIC & TRAUMA SURGERY, Shoulder < ORTHOPAEDIC & TRAUMA SURGERY |
| | |

SCHOLARONE™
Manuscripts

Peer Review Only

Original Article

Autoimmune Connective Tissue Diseases are Associated with a Risk of Rotator Cuff Repair Surgery

Shih-Wei Huang^{1,2,3} MD, Che-Li Lin^{3,4} MD, Li-Fong Lin^{1,5} PhD, Chi-Chang Huang³ PhD, Tsan-Hon

Liou^{1,2} MD, PhD, Hui-Wen Lin^{6,7*} PhD

Running title: ATCD increase the risk of rotator cuff surgery

¹Department of Physical Medicine and Rehabilitation, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan

²Department of Physical Medicine and Rehabilitation, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

³Graduate Institute of Sports Science, National Taiwan Sport University, Taoyuan, Taiwan

⁴Department of Orthopedic Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan

⁵Institute of Gerontology and Health Management, Taipei Medical University, Taipei, Taiwan

⁶Department of Mathematics, Soochow University, Taipei, Taiwan

⁷Evidence-Based Medicine Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan

*Address for reprints:

Hui-Wen Lin, PhD

Department of Mathematics, Soochow University, 70 Linhsi Road, Shihlin, Taipei, Taiwan

Tel: 886-2-2881-9471 ext. 6701

Fax: 886-2-8861-1230

E-mail: linhw@tmu.edu.tw

Abstract

Objectives

Autoimmune connective tissue diseases (ACTDs) commonly involve joint and muscle-related soft tissues, but clinical epidemiological studies investigating ACTDs involving tendons are scant. We investigated rotator cuff (RC) repair surgery risk in ACTD patients.

Design

Nationwide population-based case-control study.

Setting

All healthcare facilities in Taiwan.

Participants

A total of 30,114 patients were enrolled.

Methods

We conducted a retrospective cohort study with a 7-year longitudinal follow-up in Taiwan. Patients who had received systemic lupus erythematosus, systemic sclerosis, sicca syndrome, dermatomyositis, and polymyositis diagnoses between 2004 and 2008 were enrolled. The control cohort comprised age- and sex-matched controls. The hazard ratio (HR) and adjusted HR (aHR) were estimated between the ACTD and control cohorts after adjustment for confounders. Effects of steroid and nonsteroidal anti-inflammatory drug (NSAID) use on RC surgery risk were analysed.

Results

We enrolled 5,019 ACTD patients and 25,095 controls in the ACTD and control cohorts, respectively. RC surgery incidence was 49 and 24 per 100,000 person-years in the ACTD and control cohorts, respectively. In the ACTD cohort, the crude HR for RC surgery was 2.08 (95% confidence interval [CI], 1.08–4.02, $P < 0.05$), and the aHR was 1.97 (95% CI, 1.01–3.82, $P < 0.05$). The ACTD patients who used NSAIDs had an aHR of 3.13 (95% CI, 1.21–8.07, $P < 0.05$) compared with controls, but the ACTD patients who used steroids did not have a significantly higher than controls.

Conclusions

ACTD patients have risk of RC repair surgery. ACTD patients with steroids are at a low risk of surgery, and aggressive inflammation control may be a strategy for managing subsequent lesions of the RC.

Keywords: Autoimmune connective tissue diseases; rotator cuff surgery; risk factor; population-

1
2
3 based study
4
5
6
7
8

9 **Strengths and limitations of this study**
10

- 11 - First large-scale, population-based study for risk of rotator cuff lesion among autoimmune
12
13 connective tissue diseases (ACTD) patients.
14
15 - Compared with control cohort, patients with ACTD had higher risk of receiving rotator cuff
16
17 repair surgery
18
19 - Steroid use can lower the risk of receiving rotator cuff repair surgery among ACTD patients.
20
21 - In addition to joint and muscle lesions, we should also pay attention to tendon lesion and
22
23 controlling the inflammation process could be a potentially effective prevention strategy for the
24
25 requirement of receiving rotator cuff repair surgery.
26
27
28
29 - The detailed information of ACTD severity cannot be presented in this population based study.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Autoimmune connective tissue diseases (ACTDs), such as systemic lupus erythematosus (SLE), systemic sclerosis, sicca syndrome, dermatomyositis, and polymyositis, are systemic autoimmune disorders that affect multiple organ systems and exhibit intermittent relapse and remission. Owing to the various organs involved the chronic inflammatory process caused by autoantibody deposition and related inflammatory reactions, ACTD patients, particularly SLE patients, usually present heterogeneous clinical manifestations.[1] The musculoskeletal system is one of the organ systems that is often affected, and initial musculoskeletal symptoms are often similar to those of autoimmune diseases.[2] The severity of clinical musculoskeletal symptoms varies among individuals. SLE patients can present mild arthralgia, without deformity or erosion, nonerosive deforming arthritis, or erosive symmetric polyarthritis. In addition to arthritis and arthralgia, the musculoskeletal symptoms of SLE patients include osteonecrosis, tendonitis, myositis, and tendon rupture.[3] However, few studies have investigated and emphasised the lesions of the enthesis in SLE patients in connection with other ACTDs.[4 5]

Rotator cuff (RC) tear or rupture is one of the most common causes of shoulder dysfunction. RC tears may be asymptomatic, or their clinical presentations can be pain accompanied by a limited range of movement. RC disorders are observed in 30%–70% of patients presenting with shoulder

1
2
3
4 pain, and the incidence of RC tears is 5%–40%. [6] Because RC tears can be asymptomatic, different
5
6
7 studies have reported diverse prevalence rates of RC tears. An ultrasound screening study revealed
8
9
10 that the prevalence of RC tears was 20.47% among 1366 shoulders with or without clinical
11
12
13 symptoms, and the prevalence increased with age. [7] Initially, RC tears can be treated using
14
15
16 conventional methods such as exercise or injections. [8] Patients with extensive RC tears experience
17
18
19 limited shoulder function while performing daily activities or working, and surgical repair is
20
21
22 recommended to relieve symptoms and restore function. RC repair surgery and subsequent possible
23
24
25 complications can increase patients' medical expenditure and the economic burden on the health care
26
27
28 system. [9]

29
30
31
32
33
34 A recent cross-sectional study investigating hand tendon findings revealed the predominance of
35
36
37 tenosynovitis or tendonitis. [10] Case reports have described rupture of patellar and hand tendons in
38
39
40 SLE patients. [11 12] Thus, we hypothesise that SLE patients have a relatively high risk of RC repair
41
42
43 surgery due to tendon lesions. In addition, case reports of tendon rupture have mentioned other
44
45
46 ACTDs, such as dermatomyositis. [13] However, sufficient epidemiological research is not available
47
48
49 to prove that SLE and other ACTDs are risk factors for RC tears that require repair surgery.
50
51
52 Therefore, we conducted this longitudinal retrospective case–control cohort study to identify the
53
54
55 temporal association between ACTD and the risk of RC repair surgery.
56
57
58
59
60

Methods

Study design

Using a health care database, this longitudinal retrospective case–control cohort study analysed the risk of RC repair surgery. In the study cohort, we included patients who had been diagnosed with ACTD between 1 January 2004 and 31 December 2008. Their data were obtained from the National Health Insurance Research Database (NHIRD) of Taiwan. A control cohort consisting of five age- and sex-matched non-ATCD controls per ATCD patient was obtained using the same database. The follow-up period was 7 years, till the end of 2010. The follow-up period ended when the patients or controls received RC repair surgery. To ensure patient privacy, the names and identity numbers were replaced by numbers and letters from the English alphabet codes, which are used for identifying patient data in the NHIRD. Because the linked identity data were removed, the patient data from the NHIRD could not be identified; hence, the requirement of informed consent was waived in this study. This study was approved by institutional review board of a university in Taipei.

A brief background on Taiwan's National Health Insurance, NHIRD, and Longitudinal Health Insurance Database 2005

1
2
3
4 The National Health Insurance (NHI) system of Taiwan, a form of social insurance, covers
5
6 more than 96% of the population of Taiwan.[14 15] The NHI programme covers almost all medical
7
8 services such as outpatient visits, admission service, and emergency hospitalisation. Diagnoses made
9
10 using International Classification of Diseases Ninth Revision, Clinical Modification (ICD-9-CM)
11
12 codes, medical prescriptions, procedures, and surgery are recorded in the NHIRD. The data used in
13
14 this study were obtained from the Taiwan Longitudinal Health Insurance Database 2005 (LHID2005).
15
16 The LHID2005 contains the data of 1,000,000 beneficiaries randomly sampled from the Registry for
17
18 Beneficiaries of the NHIRD. For research purposes, the National Health Research Institutes of
19
20 Taiwan collect and maintain registration files and original claims data from the NHI administration
21
22 and then release them publicly through the NHIRD.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Inclusion and exclusion criteria

1
2
3
4 The study cohort included ACTD patients diagnosed with SLE (ICD-9-CM code 710.0),
5
6 systemic sclerosis (ICD-9-CM code 710.1), sicca syndrome (ICD-9-CM code 710.2),
7
8 dermatomyositis (ICD-9-CM code 710.3), and polymyositis (ICD-9-CM code 710.4) by using the
9
10 American College of Rheumatology criteria between 1 January 2004 and 31 December 2008. To
11
12 ensure the high accuracy of ACTD diagnosis, this study selected only patients who were diagnosed
13
14 with ACTDs at least twice consistently, according to ICD-9-CM codes, in outpatient clinics or those
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 who had a primary diagnosis of ACTDs during hospitalisation within 1 year and were older than 20
5
6
7 years. ACTD patients who had undergone RC repair surgery before 2004, who had missing data, and
8
9
10 who died during the follow-up period were excluded from this study. Finally, 5,019 SLE patients
11
12
13 were enrolled in the study cohort (Figure 1).
14
15
16
17
18

19 Confounders and propensity score adjustment

20
21 In addition to the demographic variables of age and sex, economic status and comorbidities, such as
22
23
24 diabetes mellitus (ICD-9-CM codes 250 and 251), hypertension (ICD-9-CM codes 401–405),
25
26
27 hyperlipidaemia (ICD-9-CM codes 272.0–272.4), coronary heart disease, gout, steroid use, thyroid
28
29
30 disorders, and fractures, were analysed in this study. To minimise the bias of data selection from the
31
32
33 study database, we used propensity scores adjusted for comorbidities and income, as shown in Table
34
35
36
37 1.
38
39
40
41
42

43 Outcome identification

44
45 We used the first RC repair surgery with the relevant application codes (64121B and 64122B)
46
47
48 as the study endpoint. All participants were followed up from the index date to the endpoint or until
49
50
51 31 December 2010, whichever was earlier, and the final-date observations were censored
52
53
54 observations.
55
56
57
58
59
60

Statistical Analysis

Demographic characteristics and comorbidities were analysed using Pearson's chi-square test.

We calculated the incidence of ACTDs and compared the risk of RC repair surgery between the two cohorts by using the Cox model after propensity score adjustment. Furthermore, we compared the risk of repair surgery in the ACTDs patients who did or did not receive medication (nonsteroidal anti-inflammatory drugs [NSAIDs] and steroids) with non-ACTD controls. To clarify the association between medication and RC tears, Kaplan–Meier hazard curves were plotted for RC tears in ACTDs patients who did or did not receive NSAIDs and controls as well as in ACTDs patients who did or did not receive steroids and controls for a 7-year follow-up period. All data analyses were performed using the Stata package (Version 11) and SAS statistical package (Version 9.1.3; SAS Institute, Cary, NC, USA). A value of $P < 0.05$ was considered statistically significant.

Patient involvement

No patients were involved in developing the hypothesis, the specific aims or the research questions, nor were they involved in developing plans for design or implementation of the study. No patients were involved in the interpretation of study results or write up of the manuscript. There are no plans to disseminate the results of the research to study participants or the relevant patient community.

Results

Women constituted 77.5% in both cohorts, and the prevalence of the comorbidities of hyperlipidaemia, coronary heart disease, gout, and thyroid disorders were higher in the ACTD cohort than in the control cohort (Table 1). The incidence of RC repair surgery was 49.0 and 24.0 per 100,000 person-years in the ACTD and control cohorts, respectively. In the ACTD cohort, the crude hazard ratio (HR) of RC repair surgery was 2.08 (95% CI, 1.08–4.02, $P < 0.05$), and the adjusted HR (aHR) was 1.97 (95% CI, 1.01–3.82, $P < 0.05$) (Table 2). Figure 2A shows the Kaplan–Meier hazard curves for the risk of RC repair surgery in the ACTD and control cohorts during the 7-year follow-up period. A comparison of the ACTD patients who did and did not use NSAIDs (separately) with controls revealed that the ACTD patients with records of NSAID use had a higher risk of RC repair surgery (aHR = 3.13, 95% CI, 1.21–8.07, $P < 0.05$) than did the ACTD patients without records of NSAID use (Table 3). Figure 2B shows the Kaplan–Meier hazard curves for the risk of RC repair surgery in the ACTD patients who used NSAIDs, the ACTD patients who did not use NSAIDs, and controls during the 7-year follow-up period. Further analysis of the association between steroid use and the risk of RC repair surgery showed that the crude HR was 2.32 (95% CI, 1.21–8.07, $P < 0.05$) among ACTD patients who used steroids. However, the aHR of the risk of surgery was not significantly higher in the ACTD patients than in controls (Table 4). Figure 2C represents the trend of the risk of RC repair surgery; the risk increased among the ACTD patients who used steroids but

1
2
3
4 was not significant during the 7 year follow-up period.
5
6
7
8
9
10
11

12 **Discussion**

13
14
15 Although case reports have described spontaneous ruptures in the supraspinatus tendon and the
16 patellar tendon and hand flexor tendon,[11-13 16] no relevant epidemiological study has investigated
17
18 the risk of RC lesions among ACTD patients until now. Our population-based cohort study revealed
19
20 that the ACTD patients had a higher risk of RC repair surgery than controls. This finding indicates
21
22 that in addition to the joints, the periarticular soft tissue is affected in ACTDs. During the 7-year
23
24 longitudinal follow-up period, the number of events of RC repair surgery increased with ACTD
25
26 progression. To improve the quality of life and prevent the negative effects of RC injuries among
27
28 ACTD patients, identifying the possible mechanism of ACTD pathogenesis is crucial for developing
29
30 an effective prevention strategy.
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 The factors involved in RC injury pathogenesis can typically be classified into extrinsic and
46
47 intrinsic factors. [17] For ACTD patients, we suppose that intrinsic pathogenic aetiologies play a
48
49 crucial role in increasing the risk of RC injuries and the subsequent requirement of repair surgery.
50
51
52
53
54 ACTD patients exhibit the characteristics of systemic inflammatory processes, and inflammation
55
56
57
58
59
60

1
2
3
4 reactions subsequently affect the RC tendon. Subclinical inflammation persists in ACTD patients
5
6
7 even after clinical symptoms are under control. Subclinical chronic inflammation can disrupt the
8
9
10 tendon healing and remodelling process. It can lead to weakening of the tendon, thus increasing the
11
12
13 risk of subsequent tendon rupture. Previous case reports have also found perivascular mononuclear
14
15
16 cell infiltration in the ruptured tendon, which was caused by the ACTD inflammatory process. [18
17
18
19] The inflammatory phenomenon can also be detected using ultrasound techniques. A study
20
21
22 reported that 49.4% of ultrasound abnormalities were tenosynovitis. [20] In addition to tenosynovitis,
23
24
25 ultrasound detected chronic tendinopathy, which led to degeneration of the tendon. The weakened
26
27
28 structure was highly vulnerable to injuries. These intrinsic aetiologies of tendon inflammation and
29
30
31 subsequent tendon degeneration can lead a high risk of RC injuries and the subsequent requirement
32
33
34 of repair surgery among ACTD patients.

35
36
37
38
39
40 ACTDs represent complicated chronic inflammatory autoimmune diseases that do not have curative
41
42
43 treatment. To arrest the progression of autoimmune diseases, systemic steroids are often used and
44
45
46 combined with nonsteroidal medication to control flare-up episodes. [21] Corticosteroids can
47
48
49 accelerate weakness progression by inhibiting collagen synthesis and impairing blood supply. [22]
50
51
52 Corticosteroids inhibit collagen synthesis and may also impair blood supply, thus weakening the
53
54
55 tendons. [5] A critical zone near the insertion of the supraspinatus has been described using
56
57
58
59
60

1
2
3
4 microangiographic evidence of an area of hypovascularity in the tendon close to its humeral
5
6
7 insertion. Relative ischaemia in this zone is reported to mimic tendon degeneration. [6] Previous
8
9
10 studies have also mentioned that chronic synovitis, tenosynovitis, and long-term steroid use can lead
11
12
13 to degeneration and thus increase the vulnerability of the flexor tendon in ACTD patients. [23 24]
14
15
16 However, our study revealed that steroid use in all the patients and controls did not significantly
17
18
19 increase the risk of RC repair surgery. Studies have shown that inflammatory changes occur at the
20
21
22 site of tendon rupture; these changes have been observed in patients with ACTDs. [18 25] Although
23
24
25 steroids can lead to tendon degeneration, inflammatory processes can be arrested by steroid
26
27
28 administration. We hypothesised that the net effect of steroid use can increase the risk of RC repair
29
30
31 surgery, but this effect was not significant in ACTD patients. Furthermore, ACTD-induced chronic
32
33
34 inflammatory process and related degeneration can accelerate the weakening of the RC with ageing.
35
36
37 When the fracture statuses of both cohorts were compared, both fracture and nonfracture statuses
38
39
40 increased the risk of RC repair surgery in the ACTD cohort. The intrinsic pathogenesis factor may be
41
42
43 the major cause of RC lesions among ACTD patients.
44
45
46
47

48
49 Our study revealed that ACTD is a risk factor for RC repair surgery. We hypothesised the
50
51
52 possible mechanism underlying this association was chronic inflammation and tendon degeneration,
53
54
55 which damage and weaken the RC structure. The strength of this study was its large sample size and
56
57
58
59
60

1
2
3
4 data analysis. Moreover, it is the first epidemiological study to investigate the association between
5
6
7 ACTDs and the risk of RC lesions and surgery. Nevertheless, several limitations of this study need to
8
9
10 be addressed. First, the diagnosis of ACTDs and comorbidities were defined using ICD codes from
11
12 the database; hence, accuracy should be examined. For accurate payment, the Bureau of NHI reviews
13
14 the medical records regularly. SLE, dermatomyositis, and polymyositis patients in Taiwan can apply
15
16 for catastrophic illness registration cards, and copayment is free for SLE-related medical problems
17
18 from the Bureau. Second, laboratory data of the inflammatory status and severity of ACTDs cannot
19
20 be obtained from the database. The severity and status of ACTDs cannot be categorised in the
21
22 database, and we cannot identify which status of ACTDs patients were at a high risk of tendon
23
24 lesions. Third, extrinsic factors affecting RC injuries include repeated impingement and overuse
25
26 during work and daily living activities. These factors can increase the risk of repair surgery.
27
28 However, data on work status, daily activities, body weight, alcohol consumption, and smoking are
29
30 not available in the database. Although a large sample size was obtained from this database, these
31
32 confounders cannot be excluded completely in this study. Finally, for higher accuracy, we only
33
34 investigated the risk of RC lesions and the requirement of subsequent repair surgery; therefore,
35
36 patients with minor tears or those who did not require surgical intervention may have been missed.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Despite the limited information available on the types of RC lesions, our population-based study provided crucial information on the high risk of RC surgery among ACTD patients.

Conclusion

The results of this 7-year longitudinal population-based case-control cohort study showed that ACTD patients have a 1.97-fold higher risk of RC repair surgery than do controls. Additional studies on inflammatory severity in ACTDs and the effects of ACTD-related medication on the risk of RC lesions are recommended.

Acknowledgments: None

Contributors: H-SW participated in the study design, conducted the data analysis, drafted the initial manuscript and approved the final manuscript as submitted. L-CL conducted the data analysis, drafted the manuscript and approved the final manuscript as submitted. L-LF contributed to the study design, reviewed and revised the manuscript, and approved the final manuscript as submitted. H-CC reviewed and revised the manuscript, and approved the final manuscript as submitted. L-TH participated in the study design, reviewed and revised the manuscript, and approved the final manuscript as submitted. RE designed and conceptualised the study, and approved the final manuscript as submitted. L-HW participated in the study design, conducted the data analysis, revised manuscript and approved the final manuscript as submitted.

Funding: None

Competing interests: None declared.

1
2
3 Ethics approval: The Institutional Review Board of a Taipei University (N20170724)

4
5 Data sharing statement: From HuiWen Lin, linhw@tmu.edu.tw

6
7
8
9 Provenance and peer review: Not commissioned; externally peer reviewed.

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Reference

1. Tsokos GC. Systemic lupus erythematosus. *The New England journal of medicine* 2011;**365**(22):2110-21 doi: 10.1056/NEJMra1100359[published Online First: Epub Date]].
2. Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. *Clinics in dermatology* 2006;**24**(5):348-62 doi: 10.1016/j.clindermatol.2006.07.014[published Online First: Epub Date]].
3. Zoma A. Musculoskeletal involvement in systemic lupus erythematosus. *Lupus* 2004;**13**(11):851-3 doi: 10.1191/0961203303lu2021oa[published Online First: Epub Date]].
4. Gutierrez M, Filippucci E, De Angelis R, et al. Subclinical enthesal involvement in patients with psoriasis: an ultrasound study. *Seminars in arthritis and rheumatism* 2011;**40**(5):407-12 doi: 10.1016/j.semarthrit.2010.05.009[published Online First: Epub Date]].
5. Grossman JM. Lupus arthritis. *Best practice & research. Clinical rheumatology* 2009;**23**(4):495-506 doi: 10.1016/j.berh.2009.04.003[published Online First: Epub Date]].
6. Oliva F, Piccirilli E, Bossa M, et al. I.S.Mu.L.T - Rotator Cuff Tears Guidelines. *Muscles, ligaments and tendons journal* 2015;**5**(4):227-63 doi: 10.11138/mltj/2015.5.4.227[published Online First: Epub Date]].
7. Yamamoto A, Takagishi K, Osawa T, et al. Prevalence and risk factors of a rotator cuff tear in the general population. *Journal of shoulder and elbow surgery* 2010;**19**(1):116-20 doi: 10.1016/j.jse.2009.04.006[published Online First: Epub Date]].
8. Abdul-Wahab TA, Betancourt JP, Hassan F, et al. Initial treatment of complete rotator cuff tear and transition to surgical treatment: systematic review of the evidence. *Muscles, ligaments and tendons journal* 2016;**6**(1):35-47 doi: 10.11138/mltj/2016.6.1.035[published Online First: Epub Date]].
9. Colvin AC, Egorova N, Harrison AK, et al. National trends in rotator cuff repair. *The Journal of bone and joint surgery. American volume* 2012;**94**(3):227-33 doi: 10.2106/JBJS.J.00739[published Online First: Epub Date]].
10. Ogura T, Hirata A, Hayashi N, et al. Comparison of ultrasonographic joint and tendon findings in hands between early, treatment-naïve patients with systemic lupus erythematosus and rheumatoid arthritis. *Lupus* 2017;**26**(7):707-14 doi: 10.1177/0961203316676375[published Online First: Epub Date]].
11. Albayrak I, Kucuk A, Arslan S, et al. Spontaneous patellar tendon rupture in a case followed up for diagnosis of systemic lupus erythematosus. *European journal of rheumatology* 2014;**1**(4):159-60 doi: 10.5152/eurjrheumatol.2014.140044[published Online First: Epub Date]].
12. Hosokawa T, Oda R, Toyama S, et al. Spontaneous flexor tendon rupture due to an insufficiency fracture of the hamate hook in a patient with systemic lupus erythematosus: A case report.

- International journal of surgery case reports 2016;**27**:63-65 doi:
10.1016/j.ijscr.2016.06.052[published Online First: Epub Date]].
13. Nakamura S, Nakagawa J. Recurrent extensor tendon rupture in adult-onset dermatomyositis: a case report. *Clinical rheumatology* 2005;**24**(4):409-10 doi: 10.1007/s10067-004-1050-0[published Online First: Epub Date]].
14. Cheng TM. Taiwan's new national health insurance program: genesis and experience so far. *Health affairs* 2003;**22**(3):61-76 doi: 10.1377/hlthaff.22.3.61[published Online First: Epub Date]].
15. Cheng SH, Chiang TL. The effect of universal health insurance on health care utilization in Taiwan. Results from a natural experiment. *Jama* 1997;**278**(2):89-93
16. Prabu VN, Agrawal S, Kishore JK, et al. Supraspinatus tendon rupture in lupus: a rarity. *Lupus* 2009;**18**(11):1026-7 doi: 10.1177/0961203309103099[published Online First: Epub Date]].
17. Via AG, De Cupis M, Spoliti M, et al. Clinical and biological aspects of rotator cuff tears. *Muscles, ligaments and tendons journal* 2013;**3**(2):70-9 doi:
10.11138/mltj/2013.3.2.070[published Online First: Epub Date]].
18. Potasman I, Bassan HM. Multiple tendon rupture in systemic lupus erythematosus: case report and review of the literature. *Annals of the rheumatic diseases* 1984;**43**(2):347-9
19. Lu M, Johar S, Veenema K, et al. Patellar tendon rupture with underlying systemic lupus erythematosus: a case report. *The Journal of emergency medicine* 2012;**43**(1):e35-8 doi:
10.1016/j.jemermed.2009.08.054[published Online First: Epub Date]].
20. Di Matteo A, De Angelis R, Cipolletta E, et al. Systemic lupus erythematosus arthropathy: the sonographic perspective. *Lupus* 2017:961203317747716 doi:
10.1177/0961203317747716[published Online First: Epub Date]].
21. Thamer M, Hernan MA, Zhang Y, et al. Prednisone, lupus activity, and permanent organ damage. *The Journal of rheumatology* 2009;**36**(3):560-4 doi: 10.3899/jrheum.080828[published Online First: Epub Date]].
22. Halpern AA, Horowitz BG, Nagel DA. Tendon ruptures associated with corticosteroid therapy. *The Western journal of medicine* 1977;**127**(5):378-82
23. Zayat AS, Md Yusof MY, Wakefield RJ, et al. The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review. *Rheumatology* 2016;**55**(3):485-94 doi: 10.1093/rheumatology/kev343[published Online First: Epub Date]].
24. Alves EM, Macieira JC, Borba E, et al. Spontaneous tendon rupture in systemic lupus erythematosus: association with Jaccoud's arthropathy. *Lupus* 2010;**19**(3):247-54 doi:
10.1177/0961203309351729[published Online First: Epub Date]].
25. Furie RA, Chartash EK. Tendon rupture in systemic lupus erythematosus. *Seminars in arthritis and rheumatism* 1988;**18**(2):127-33

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4 Figure Legends


5
6 Figure 1 Flowchart showing the study design

7
8
9 Figure 2A Kaplan–Meier hazard curve for rotor cuff tear in autoimmune connective tissue disease
10 patients and controls for an up to 7-year follow-up period.

11
12
13 Figure 2B Kaplan–Meier hazard curve for rotor cuff tear in autoimmune connective tissue disease
14 (ACTD) patients with or without nonsteroidal anti-inflammatory drug use and controls over a 7-year
15 follow-up period.

16
17
18
19 Figure 2C Kaplan–Meier hazard curve for rotor cuff tear in autoimmune connective tissue diseases
20 (ACTDs) patients with or without steroid use and controls over a 7-year follow-up period.

Figure 1



Autoimmune connective tissue diseases (ACTDs)

Figure 2A.




Figure 2B.





Figure 2C.



STROBE Statement

Checklist of items that should be included in reports of observational studies

| Section/Topic | Item No | Recommendation | Reported on Page No |
|---------------------------|---------|--|---------------------|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | 2 |
| | | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 3 |
| Introduction | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 4 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 5 |
| Methods | | | |
| Study design | 4 | Present key elements of study design early in the paper | 6 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 6-7 |
| Participants | 6 | (a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | 7-8 |
| | | <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls | |
| | | <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants | |
| Variables | 7 | (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed | 8 |
| | | <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case | |
| Data sources/measurement | 8* | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 8 |
| Bias | 9 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 7-8 |
| Study size | 10 | Describe any efforts to address potential sources of bias | 8 |
| Quantitative variables | 11 | Explain how the study size was arrived at | 8 |
| Statistical methods | 12 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 7-8 |
| | | (a) Describe all statistical methods, including those used to control for confounding | 9 |
| | | (b) Describe any methods used to examine subgroups and interactions | |
| | | (c) Explain how missing data were addressed | |
| | | (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed | |
| | | <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed | |
| | | <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy | |
| | | (e) Describe any sensitivity analyses | |

| Section/Topic | Item No | Recommendation | Reported on Page No |
|--------------------------|---------|--|---------------------|
| Results | | | |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 9-10 |
| | | (b) Give reasons for non-participation at each stage | 9-10 |
| | | (c) Consider use of a flow diagram | 9-10 |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 9-10 |
| | | (b) Indicate number of participants with missing data for each variable of interest | |
| | | (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) | |
| Outcome data | 15* | <i>Cohort study</i> —Report numbers of outcome events or summary measures over time | |
| | | <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure | 9-10 |
| | | <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures | |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 9-10 |
| | | (b) Report category boundaries when continuous variables were categorized | |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | |
| Discussion | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 10 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 14 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 10-14 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 14 |
| Other Information | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 15 |

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Autoimmune Connective Tissue Diseases Increase the Risk of Rotator Cuff Repair Surgery: a Population-Based Retrospective Cohort Study

| | |
|---------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2018-023848.R1 |
| Article Type: | Research |
| Date Submitted by the Author: | 11-Sep-2018 |
| Complete List of Authors: | Huang, ShihWei; Shuang Ho Hospital, Physical Medicine and Rehabilitation Lin, CheLi; Taipei Medical University Shuang Ho Hospital, Orthopedics Lin, LiFong; Shuang Ho Hospital, Physical Medicine and Rehabilitation Huang, ChiChang; Graduate Institute of Sports Science, National Taiwan Sport University Liou, Tsan-Hon; Shuang Ho Hospital, Physical Medicine and Rehabilitation Lin, Hui-Wen; Department of Mathematics, Soochow University |
| Primary Subject Heading: | Rheumatology |
| Secondary Subject Heading: | Rehabilitation medicine, Sports and exercise medicine |
| Keywords: | Rheumatology < INTERNAL MEDICINE, Orthopaedic sports trauma < ORTHOPAEDIC & TRAUMA SURGERY, Shoulder < ORTHOPAEDIC & TRAUMA SURGERY |
| | |

SCHOLARONE™
Manuscripts

Original Article

Autoimmune Connective Tissue Diseases Increase the Risk of Rotator Cuff Repair Surgery: a
Population-Based Retrospective Cohort Study

Shih-Wei Huang^{1,2,3} MD, Che-Li Lin^{3,4} MD, Li-Fong Lin^{1,5} PhD, Chi-Chang Huang³ PhD, Tsan-Hon
Liou^{1,2} MD, PhD, Hui-Wen Lin^{6,7*} PhD

Running title: ATCD increase the risk of rotator cuff surgery

¹Department of Physical Medicine and Rehabilitation, Shuang Ho Hospital, Taipei Medical
University, Taipei, Taiwan

²Department of Physical Medicine and Rehabilitation, School of Medicine, College of Medicine,
Taipei Medical University, Taipei, Taiwan

³Graduate Institute of Sports Science, National Taiwan Sport University, Taoyuan, Taiwan

⁴Department of Orthopedic Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei
City, Taiwan

⁵Institute of Gerontology and Health Management, Taipei Medical University, Taipei, Taiwan

⁶Department of Mathematics, Soochow University, Taipei, Taiwan

⁷Evidence-Based Medicine Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan

*Address for reprints:

Hui-Wen Lin, PhD

Department of Mathematics, Soochow University, 70 Linhsi Road, Shihlin, Taipei, Taiwan

Tel: 886-2-2881-9471 ext. 6701

Fax: 886-2-8861-1230

E-mail: linhw@s.tmu.edu.tw

Abstract

Objectives

Autoimmune connective tissue diseases (ACTDs) commonly involve shoulder joint, but clinical epidemiological studies investigating association of tendons are scant. When rotator cuff (RC) tears, it can cause shoulder disability, and surgical intervention is usually required. The aim of this study was to investigate rotator cuff (RC) repair surgery risk in ACTD patients. The secondary aim was to investigate the effect of anti-inflammatory medication for risk of RC repair surgery risk.

Methods

We conducted a retrospective cohort study with a 7-year longitudinal follow-up period. Patients with systemic lupus erythematosus, systemic sclerosis, sicca syndrome, dermatomyositis, and polymyositis diagnoses between 2004 and 2008 were enrolled. The control cohort comprised age- and sex-matched controls. The hazard ratio (HR) and adjusted HR (aHR) were estimated for the risk of RC surgery between the ACTD and control cohorts after adjustment for confounders. Effects of steroid and nonsteroidal anti-inflammatory drug (NSAID) use on for HR and aHR of RC surgery risk were also analysed.

Results

We enrolled 5,019 ACTD patients and 25,095 controls in the ACTD and control cohorts, respectively. RC surgery incidence was 49 and 24 per 100,000 person-years in the ACTD and control cohorts, respectively. In the ACTD cohort, the crude HR for RC surgery was 2.08 (95% confidence interval [CI], 1.08–4.02, $P < 0.05$), and the aHR was 1.97 (95% CI, 1.01–3.82, $P < 0.05$). The ACTD patients who used NSAIDs had an aHR of 3.13 (95% CI, 1.21–8.07, $P < 0.05$) compared with controls, but the ACTD patients who used steroids did not have a significantly higher than controls.

Conclusions

ACTD patients had increased risk of RC repair surgery. However, there was no difference of RC surgery risk with comparing control cohort when steroid using. It could indicate that inflammation control may be a strategy for managing subsequent lesions of the RC.

Keywords: Autoimmune connective tissue diseases; rotator cuff surgery; risk factor; population-based study

Strengths and limitations of this study

- First large-scale, population-based study for risk of rotator cuff lesion among autoimmune connective tissue diseases (ACTD) patients.
- The detailed information of ACTD severity cannot be presented in this population based study.
- Although steroid can lower the risk of rotator cuff repair surgery among ACTD patients, our study didn't analysed disease-modifying anti-rheumatic drugs (DMARDs), which could influence the inflammatory status of study cohort.
- For better accuracy of study outcome, we only investigated the risk of RC lesions and the requirement of subsequent repair surgery; therefore, patients with minor tears or those who did not require surgical intervention may have been missed in this study.

Introduction

Autoimmune connective tissue diseases (ACTDs), such as systemic lupus erythematosus (SLE), systemic sclerosis, sicca syndrome, dermatomyositis, and polymyositis, are systemic autoimmune disorders that affect multiple organ systems and exhibit intermittent relapse and remission. Owing to the various organs involved the chronic inflammatory process caused by autoantibody deposition and related inflammatory reactions, ACTD patients, particularly SLE patients, usually present heterogeneous clinical manifestations.[1] The musculoskeletal system is one of the organ systems that is often affected, and initial musculoskeletal symptoms are often similar to those of autoimmune diseases.[2] The severity of clinical musculoskeletal symptoms varies among individuals. SLE patients can present mild arthralgia, without deformity or erosion, nonerosive deforming arthritis, or erosive symmetric polyarthritis. In addition to arthritis and arthralgia, the musculoskeletal symptoms of SLE patients include osteonecrosis, tendonitis, myositis, and tendon rupture.[3] However, few studies have investigated and emphasised the lesions of the enthesis in SLE patients in connection with other ACTDs.[4 5]

Rotator cuff (RC) tear or rupture is one of the most common causes of shoulder dysfunction. RC tears may be asymptomatic, or their clinical presentations can be pain accompanied by a limited range of movement. RC disorders are observed in 30%–70% of patients presenting with shoulder

1
2
3
4 pain, and the incidence of RC tears is 5%–40%.[6] Because RC tears can be asymptomatic, different
5
6
7 studies have reported diverse prevalence rates of RC tears. An ultrasound screening study revealed
8
9
10 that the prevalence of RC tears was 20.47% among 1366 shoulders with or without clinical
11
12
13 symptoms, and the prevalence increased with age.[7] Initially, RC tears can be treated using
14
15
16 conventional methods such as exercise or injections.[8] Patients with extensive RC tears experience
17
18
19 limited shoulder function while performing daily activities or working, and surgical repair is
20
21
22 recommended to relieve symptoms and restore function. RC repair surgery and subsequent possible
23
24
25 complications can increase patients' medical expenditure and the economic burden on the health care
26
27
28 system.[9]
29
30
31
32

33
34 A recent cross-sectional study investigating hand tendon findings revealed the predominance of
35
36
37 tenosynovitis or tendonitis.[10] Case reports have described rupture of patellar and hand tendons in
38
39
40 SLE patients. [11 12] Thus, we hypothesise that SLE patients have a relatively high risk of RC repair
41
42
43 surgery due to tendon lesions. In addition, case reports of tendon rupture have mentioned other
44
45
46 ACTDs, such as dermatomyositis. [13] When massive tear of RC occurred, it can cause shoulder
47
48
49 disability, and surgical intervention is usually required. However, sufficient epidemiological research
50
51
52 is not available to prove that SLE and other ACTDs are risk factors for RC tears that require repair
53
54
55 surgery. We hypothesized that ACTDs patients had higher risk of RC lesions with requirement of
56
57
58
59
60

1
2
3
4 surgery repair. Therefore, we conducted this longitudinal retrospective cohort study to investigate the
5
6
7 risk of RC repair surgery among ACTDs patients. Moreover, we also investigate the effect of anti-
8
9
10 inflammatory medication for risk of RC repair surgery risk for ACTDs patients as secondary aim of
11
12
13 study.

14 15 16 17 18 **Methods**

19 20 21 **Study design**

22
23
24 Using a health care database, this longitudinal retrospective cohort study analysed the risk of RC
25
26
27 repair surgery for ATCD patients. In the study cohort, we included patients who had been
28
29
30 diagnosed with ACTD between 1 January 2004 and 31 December 2008. Their data were obtained
31
32
33 from the Taiwan Longitudinal Health Insurance Database 2005 (LHID2005), which was a part of
34
35
36 National Health Insurance Research Database (NHIRD) of Taiwan. A control cohort consisting of
37
38
39 five age- and sex-matched non-ATCD controls per ATCD patient was obtained using the same
40
41
42 database. The follow-up period was 7 years, till the end of 2010. The follow-up period ended when
43
44
45 the patients or controls received RC repair surgery. To ensure patient privacy, the names and
46
47
48 identity numbers were replaced by numbers and letters from the English alphabet codes, which are
49
50
51 used for identifying patient data in the NHIRD. Because the linked identity data were removed, the
52
53
54 patient data from the NHIRD could not be identified; hence, the requirement of informed consent
55
56
57
58
59
60

1
2
3
4 was waived in this study. This study was approved by University of Taipei Institutional Review
5
6
7 Board (UT-IRB No.: IRB-2018-07).
8
9
10

11
12
13 A brief background on Taiwan's National Health Insurance, NHIRD, and Longitudinal Health
14
15 Insurance Database 2005
16
17

18 The National Health Insurance (NHI) system of Taiwan, a form of social insurance, covers
19
20 more than 96% of the population of Taiwan.[14 15] The NHI programme covers almost all medical
21
22 services such as outpatient visits, admission service, and emergency hospitalisation. Diagnoses made
23
24 using International Classification of Diseases Ninth Revision, Clinical Modification (ICD-9-CM)
25
26 codes, medical prescriptions, procedures, and surgery are recorded in the NHIRD. The data used in
27
28 this study were obtained from the Taiwan LHID2005. The LHID2005 contains the data of 1,000,000
29
30 beneficiaries randomly sampled from the Registry for Beneficiaries of the NHIRD. For research
31
32 purposes, the National Health Research Institutes of Taiwan collect and maintain registration files
33
34 and original claims data from the NHI administration and then release them publicly through the
35
36
37
38
39
40
41
42
43
44
45 NHIRD.
46
47
48
49
50

51 Inclusion and exclusion criteria

52
53

54 The study cohort included ACTD patients diagnosed with SLE (ICD-9-CM code 710.0),
55
56
57
58
59
60

1
2
3
4 systemic sclerosis (ICD-9-CM code 710.1), sicca syndrome (ICD-9-CM code 710.2),
5
6
7 dermatomyositis (ICD-9-CM code 710.3), and polymyositis (ICD-9-CM code 710.4) by using the
8
9
10 American College of Rheumatology criteria between 1 January 2004 and 31 December 2008. To
11
12 ensure the high accuracy of ACTD diagnosis, this study selected only patients who were diagnosed
13
14 with ACTDs at least twice consistently, according to ICD-9-CM codes, in outpatient clinics or those
15
16 who had a primary diagnosis of ACTDs during hospitalisation within 1 year and were older than 20
17
18 years. ACTD patients who had undergone RC repair surgery before 2004, who had missing data, and
19
20 who died during the follow-up period were excluded from this study. Finally, 5,019 ACTD patients
21
22 were enrolled in the study cohort (Figure 1).
23
24
25
26
27
28
29
30
31
32

33 Confounders and propensity score adjustment

34
35
36 In addition to the demographic variables of age and sex, economic status and comorbidities, such as
37
38 diabetes mellitus (ICD-9-CM codes 250 and 251), hypertension (ICD-9-CM codes 401–405),
39
40 hyperlipidaemia (ICD-9-CM codes 272.0–272.4), coronary heart disease, gout, nonsteroidal anti-
41
42 inflammatory drugs (NSAIDs), steroid use (defined as 3 months of consecutive using), and fractures,
43
44 were analysed in this study. With concerning the thyroid diseases and the risk of rotator cuff tear, we
45
46 also analysed the thyroid disorders as one of the morbidities in this study.[16] To minimise the bias
47
48 of data selection from the study database, we used propensity scores adjusted for comorbidities and
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 income, as shown in Table 1.
5
6
7
8

9 Outcome identification

10
11 We used the first RC repair surgery with the relevant application codes (64121B and 64122B)
12
13 as the study endpoint from the same database. All participants were followed up from the index date
14
15
16 to the endpoint or until 31 December 2010, whichever was earlier, and the final-date observations
17
18
19 were censored observations.
20
21
22
23
24
25
26

27 Statistical Analysis

28
29 Demographic characteristics and comorbidities were analysed using Pearson's chi-square test.
30
31
32 We calculated the incidence of ACTDs and compared the risk of RC repair surgery between the two
33
34 cohorts by using the Cox model after propensity score adjustment. Furthermore, we compared the
35
36 risk of repair surgery in the ACTDs patients who did or did not receive medication (NSAIDs and
37
38 steroids) with non-ACTD controls. To clarify the association between medication and RC tears,
39
40
41 Kaplan–Meier hazard curves were plotted for RC tears in ACTDs patients who did or did not receive
42
43 NSAIDs and controls as well as in ACTDs patients who did or did not receive steroids and controls
44
45
46 for a 7-year follow-up period. All data analyses were performed using the Stata package (Version 11)
47
48
49 and SAS statistical package (Version 9.1.3; SAS Institute, Cary, NC, USA). A value of $P < 0.05$ was
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 considered statistically significant.
5

6 **Patient involvement**

7
8
9
10 No patients were involved in developing the hypothesis, the specific aims or the research
11
12 questions, nor were they involved in developing plans for design or implementation of the study. No
13
14 patients were involved in the interpretation of study results or write up of the manuscript. There are
15
16 no plans to disseminate the results of the research to study participants or the relevant patient
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
community.

25 **Results**

26
27
28 There were 5,019 ACTD patients in study cohort and 25,095 patients in the control cohort.
29
30
31 Women constituted 77.5% in both cohorts, and there was no statistical difference of age and sex. In
32
33 the study cohort, the prevalence of the comorbidities of hyperlipidaemia (17.8%), coronary heart
34
35 disease (13.2%), gout (12.1%), and thyroid disorders (8.3%) were higher in the ACTD cohort than in
36
37 the control cohort (Table 1). The incidence of RC repair surgery was 49.0 and 24.0 per 100,000
38
39 person-years in the ACTD and control cohorts, respectively. In the ACTD cohort, the crude hazard
40
41 ratio (HR) of RC repair surgery was 2.08 (95% CI, 1.08–4.02, $P < 0.05$), and the adjusted HR (aHR)
42
43 was 1.97 (95% CI, 1.01–3.82, $P < 0.05$) (Table 2). Figure 2 shows the Kaplan–Meier hazard curves
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
for the risk of RC repair surgery in the ACTD and control cohorts during the 7-year follow-up period.
A comparison of the ACTD patients who did and did not use NSAIDs (separately) with controls

1
2
3
4 revealed that the ACTD patients with records of NSAID use had a higher risk of RC repair surgery
5
6
7 (aHR = 3.13, 95% CI, 1.21–8.07, $P < 0.05$) than did the ACTD patients without records of NSAID
8
9
10 use (Table 3). Figure 3 shows the Kaplan–Meier hazard curves for the risk of RC repair surgery in
11
12 the ACTD patients who used NSAIDs, the ACTD patients who did not use NSAIDs, and controls
13
14
15 during the 7-year follow-up period. Further analysis of the association between steroid use and the
16
17 risk of RC repair surgery showed that the crude HR was 2.32 (95% CI, 1.03–5.22, $P = 0.042$) among
18
19 ACTD patients who used steroids. However, there was not significantly higher risk of RC surgery in
20
21 the ACTD patients than in controls of adjusted HR (aHR= 2.22, 95% CI, 0.98–5.03, $P = 0.067$) when
22
23 using steroids (Table 4). Figure 4 represents the trend of the risk of RC repair surgery; the risk
24
25 increased among the ACTD patients who used steroids but was not significant during the 7 year
26
27 follow-up period.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 Discussion

46 Although case reports have described spontaneous ruptures in the supraspinatus tendon and the
47
48 patellar tendon and hand flexor tendon,[11-13 17] no relevant epidemiological study has investigated
49
50 the risk of RC lesions among ACTD patients until now. Our population-based cohort study revealed
51
52 that the ACTD patients had a higher risk of RC repair surgery than controls. This finding indicates
53
54
55
56
57
58
59
60

1
2
3
4 that in addition to the joints, the periarticular soft tissue is affected in ACTDs. During the 7-year
5
6
7 longitudinal follow-up period, the number of events of RC repair surgery increased with ACTD
8
9
10 progression. To improve the quality of life and prevent the negative effects of RC injuries among
11
12
13 ACTD patients, identifying the possible mechanism of ACTD pathogenesis is crucial for developing
14
15
16 an effective prevention strategy.
17
18
19
20
21

22 The factors involved in RC injury pathogenesis can typically be classified into extrinsic and
23
24
25 intrinsic factors. [18] For ACTD patients, we suppose that intrinsic pathogenic aetiologies play a
26
27
28 crucial role in increasing the risk of RC injuries and the subsequent requirement of repair surgery.
29
30
31 ACTD patients exhibit the characteristics of systemic inflammatory processes, and inflammation
32
33
34 reactions subsequently affect the RC tendon. Subclinical inflammation persists in ACTD patients
35
36
37 even after clinical symptoms are under control. Subclinical chronic inflammation can disrupt the
38
39
40 tendon healing and remodelling process. It can lead to weakening of the tendon, thus increasing the
41
42
43 risk of subsequent tendon rupture. Previous case reports have also found perivascular mononuclear
44
45
46 cell infiltration in the ruptured tendon, which was caused by the ACTD inflammatory process. [19
47
48
49 20] The inflammatory phenomenon can also be detected using ultrasound techniques. A study
50
51
52 reported that 49.4% of ultrasound abnormalities were tenosynovitis. [21] In addition to tenosynovitis,
53
54
55 ultrasound detected chronic tendinopathy, which led to degeneration of the tendon. The weakened
56
57
58
59
60

1
2
3
4 structure was highly vulnerable to injuries. These intrinsic aetiologies of tendon inflammation and
5
6
7 subsequent tendon degeneration can lead a high risk of RC injuries and the subsequent requirement
8
9
10 of repair surgery among ACTD patients.

11
12
13
14
15 ACTDs represent complicated chronic inflammatory autoimmune diseases that do not have curative
16
17
18 treatment. To arrest the progression of autoimmune diseases, systemic steroids are often used and
19
20
21 combined with nonsteroidal medication to control flare-up episodes. [22] Corticosteroids can
22
23
24 accelerate weakness progression by inhibiting collagen synthesis and impairing blood supply. [23]
25
26
27 Corticosteroids inhibit collagen synthesis and may also impair blood supply, thus weakening the
28
29
30 tendons. [5] A critical zone near the insertion of the supraspinatus has been described using
31
32
33 microangiographic evidence of an area of hypovascularity in the tendon close to its humeral
34
35
36 insertion. Relative ischaemia in this zone is reported to mimic tendon degeneration. [6] Previous
37
38
39 studies have also mentioned that chronic synovitis, tenosynovitis, and long-term steroid use can lead
40
41
42 to degeneration and thus increase the vulnerability of the flexor tendon in ACTD patients. [24 25]
43
44
45 However, our study revealed that steroid use in all the patients and controls did not significantly
46
47
48 increase the risk of RC repair surgery. Studies have shown that inflammatory changes occur at the
49
50
51 site of tendon rupture; these changes have been observed in patients with ACTDs. [19 26] Although
52
53
54 steroids can lead to tendon degeneration, inflammatory processes can be arrested by steroid
55
56
57
58
59
60

1
2
3
4 administration. We hypothesised that the net effect of steroid use can increase the risk of RC repair
5
6
7 surgery, but this effect was not significant in ACTD patients. Furthermore, ACTD-induced chronic
8
9
10 inflammatory process and related degeneration can accelerate the weakening of the RC with ageing.

11
12
13
14
15
16 Our study revealed that ACTD is a risk factor for RC repair surgery. We hypothesised the
17
18 possible mechanism underlying this association was chronic inflammation and tendon degeneration,
19
20
21 which damage and weaken the RC structure. The strength of this study was its large sample size and
22
23
24 data analysis. Moreover, it is the first epidemiological study to investigate the association between
25
26
27 ACTDs and the risk of RC lesions and surgery. Nevertheless, several limitations of this study need to
28
29
30 be addressed. First, the diagnosis of ACTDs and comorbidities were defined using ICD codes from
31
32
33 the database; hence, accuracy should be examined. For accurate payment, the Bureau of NHI reviews
34
35
36 the medical records regularly. SLE, dermatomyositis, and polymyositis patients in Taiwan can apply
37
38
39 for catastrophic illness registration cards, and copayment is free for SLE-related medical problems
40
41
42 from the Bureau. In addition to accuracy of ACTDs diagnosis, the definite onset duration of ACTDs
43
44
45 cannot be obtained from the database and diversity of time period of follow up in study cohort are
46
47
48 needed to be addressed. Second, laboratory data of the inflammatory status and severity of ACTDs
49
50
51 cannot be obtained from the database. The severity and status of ACTDs cannot be categorised in the
52
53
54 database, and we cannot identify which status of ACTDs patients were at a high risk of tendon
55
56
57
58
59
60

1
2
3
4 lesions. Besides the disease-modifying anti-rheumatic drugs (DMARDs), which could influence the
5
6 severity of ACTDs, were not analysed because of the complexity of using from this database. Further
7
8 study about DMARDs effect for rotator cuff lesions is needed to investigate separate disease from
9
10 ACTDs in the future. Third, extrinsic factors affecting RC injuries include repeated impingement and
11
12 overuse during work and daily living activities. These factors can increase the risk of repair surgery.
13
14 However, data on work status, daily activities, body weight, alcohol consumption, and smoking are
15
16 not available in the database. Although a large sample size was obtained from this database, these
17
18 confounders cannot be excluded completely in this study. Finally, for higher accuracy, we only
19
20 investigated the risk of RC lesions and the requirement of subsequent repair surgery; therefore,
21
22 patients with minor tears or those who did not require surgical intervention may have been missed.
23
24 Despite the limited information available on the types of RC lesions, our population-based study
25
26 provided crucial information on the high risk of RC surgery among ACTD patients.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **Conclusion**

46 The results of this 7-year longitudinal population-based retrospective cohort study showed that
47
48 ACTD patients have a 1.97-fold higher risk of RC repair surgery than do controls. Additional studies
49
50 on inflammatory severity in ACTDs and the effects of ACTD-related medication on the risk of RC
51
52 lesions are recommended.
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10 Acknowledgments: None
11
12
13

14 Contributors: H-SW participated in the study design, conducted the data analysis, drafted the initial
15 manuscript and approved the final manuscript as submitted. L-CL conducted the data analysis,
16 drafted the manuscript and approved the final manuscript as submitted. L-LF contributed to the study
17 design, reviewed and revised the manuscript, and approved the final manuscript as submitted. H-CC
18 reviewed and revised the manuscript, and approved the final manuscript as submitted. L-TH
19 participated in the study design, reviewed and revised the manuscript, and approved the final
20 manuscript as submitted. RE designed and conceptualised the study, and approved the final
21 manuscript as submitted. L-HW participated in the study design, conducted the data analysis, revised
22 manuscript and approved the final manuscript as submitted.
23
24
25
26
27
28
29
30
31
32
33
34
35

36 Funding: None
37

38 Competing interests: None declared.
39

40 Ethics approval: University of Taipei Institutional Review Board (UT-IRB No.: IRB-2018-07)
41

42 Data sharing statement: From HuiWen Lin, linhw@tmu.edu.tw
43
44
45
46

47 Provenance and peer review: Not commissioned; externally peer reviewed.
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference

1. Tsokos GC. Systemic lupus erythematosus. *The New England journal of medicine* 2011;**365**(22):2110-21 doi: 10.1056/NEJMra1100359[published Online First: Epub Date]].
2. Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. *Clinics in dermatology* 2006;**24**(5):348-62 doi: 10.1016/j.clindermatol.2006.07.014[published Online First: Epub Date]].
3. Zoma A. Musculoskeletal involvement in systemic lupus erythematosus. *Lupus* 2004;**13**(11):851-3 doi: 10.1191/0961203303lu2021oa[published Online First: Epub Date]].
4. Gutierrez M, Filippucci E, De Angelis R, et al. Subclinical enthesal involvement in patients with psoriasis: an ultrasound study. *Seminars in arthritis and rheumatism* 2011;**40**(5):407-12 doi: 10.1016/j.semarthrit.2010.05.009[published Online First: Epub Date]].
5. Grossman JM. Lupus arthritis. *Best practice & research. Clinical rheumatology* 2009;**23**(4):495-506 doi: 10.1016/j.berh.2009.04.003[published Online First: Epub Date]].
6. Oliva F, Piccirilli E, Bossa M, et al. I.S.Mu.L.T - Rotator Cuff Tears Guidelines. *Muscles, ligaments and tendons journal* 2015;**5**(4):227-63 doi: 10.11138/mltj/2015.5.4.227[published Online First: Epub Date]].
7. Yamamoto A, Takagishi K, Osawa T, et al. Prevalence and risk factors of a rotator cuff tear in the general population. *Journal of shoulder and elbow surgery* 2010;**19**(1):116-20 doi: 10.1016/j.jse.2009.04.006[published Online First: Epub Date]].
8. Abdul-Wahab TA, Betancourt JP, Hassan F, et al. Initial treatment of complete rotator cuff tear and transition to surgical treatment: systematic review of the evidence. *Muscles, ligaments and tendons journal* 2016;**6**(1):35-47 doi: 10.11138/mltj/2016.6.1.035[published Online First: Epub Date]].
9. Colvin AC, Egorova N, Harrison AK, et al. National trends in rotator cuff repair. *The Journal of bone and joint surgery. American volume* 2012;**94**(3):227-33 doi: 10.2106/JBJS.J.00739[published Online First: Epub Date]].
10. Ogura T, Hirata A, Hayashi N, et al. Comparison of ultrasonographic joint and tendon findings in hands between early, treatment-naïve patients with systemic lupus erythematosus and rheumatoid arthritis. *Lupus* 2017;**26**(7):707-14 doi: 10.1177/0961203316676375[published Online First: Epub Date]].
11. Albayrak I, Kucuk A, Arslan S, et al. Spontaneous patellar tendon rupture in a case followed up for diagnosis of systemic lupus erythematosus. *European journal of rheumatology* 2014;**1**(4):159-60 doi: 10.5152/eurjrheumatol.2014.140044[published Online First: Epub Date]].
12. Hosokawa T, Oda R, Toyama S, et al. Spontaneous flexor tendon rupture due to an insufficiency fracture of the hamate hook in a patient with systemic lupus erythematosus: A case report.

- 1
2
3 International journal of surgery case reports 2016;**27**:63-65 doi:
4 10.1016/j.ijscr.2016.06.052[published Online First: Epub Date]].
5
6 13. Nakamura S, Nakagawa J. Recurrent extensor tendon rupture in adult-onset dermatomyositis: a
7 case report. *Clinical rheumatology* 2005;**24**(4):409-10 doi: 10.1007/s10067-004-1050-
8 0[published Online First: Epub Date]].
9
10 14. Cheng TM. Taiwan's new national health insurance program: genesis and experience so far.
11 *Health affairs* 2003;**22**(3):61-76 doi: 10.1377/hlthaff.22.3.61[published Online First: Epub
12 Date]].
13
14 15. Cheng SH, Chiang TL. The effect of universal health insurance on health care utilization in
15 Taiwan. Results from a natural experiment. *Jama* 1997;**278**(2):89-93
16
17 16. Oliva F, Osti L, Padulo J, et al. Epidemiology of the rotator cuff tears: a new incidence related to
18 thyroid disease. *Muscles Ligaments Tendons J* 2014;**4**(3):309-14
19
20 17. Prabu VN, Agrawal S, Kishore JK, et al. Supraspinatus tendon rupture in lupus: a rarity. *Lupus*
21 2009;**18**(11):1026-7 doi: 10.1177/0961203309103099[published Online First: Epub Date]].
22
23 18. Via AG, De Cupis M, Spoliti M, et al. Clinical and biological aspects of rotator cuff tears.
24 *Muscles, ligaments and tendons journal* 2013;**3**(2):70-9 doi:
25 10.11138/mltj/2013.3.2.070[published Online First: Epub Date]].
26
27 19. Potasman I, Bassan HM. Multiple tendon rupture in systemic lupus erythematosus: case report
28 and review of the literature. *Annals of the rheumatic diseases* 1984;**43**(2):347-9
29
30 20. Lu M, Johar S, Veenema K, et al. Patellar tendon rupture with underlying systemic lupus
31 erythematosus: a case report. *The Journal of emergency medicine* 2012;**43**(1):e35-8 doi:
32 10.1016/j.jemermed.2009.08.054[published Online First: Epub Date]].
33
34 21. Di Matteo A, De Angelis R, Cipolletta E, et al. Systemic lupus erythematosus arthropathy: the
35 sonographic perspective. *Lupus* 2017:961203317747716 doi:
36 10.1177/0961203317747716[published Online First: Epub Date]].
37
38 22. Thamer M, Hernan MA, Zhang Y, et al. Prednisone, lupus activity, and permanent organ damage.
39 *The Journal of rheumatology* 2009;**36**(3):560-4 doi: 10.3899/jrheum.080828[published
40 Online First: Epub Date]].
41
42 23. Halpern AA, Horowitz BG, Nagel DA. Tendon ruptures associated with corticosteroid therapy.
43 *The Western journal of medicine* 1977;**127**(5):378-82
44
45 24. Zayat AS, Md Yusof MY, Wakefield RJ, et al. The role of ultrasound in assessing musculoskeletal
46 symptoms of systemic lupus erythematosus: a systematic literature review. *Rheumatology*
47 2016;**55**(3):485-94 doi: 10.1093/rheumatology/kev343[published Online First: Epub Date]].
48
49 25. Alves EM, Macieira JC, Borba E, et al. Spontaneous tendon rupture in systemic lupus
50 erythematosus: association with Jaccoud's arthropathy. *Lupus* 2010;**19**(3):247-54 doi:
51 10.1177/0961203309351729[published Online First: Epub Date]].
52
53
54
55
56
57
58
59

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

26. Furie RA, Chartash EK. Tendon rupture in systemic lupus erythematosus. *Seminars in arthritis and rheumatism* 1988;**18**(2):127-33

For peer review only

1
2
3
4 Figure Legends
5

6 Figure 1 Flowchart showing the study design
7

8
9 Figure 2 Kaplan–Meier hazard curve for rotor cuff tear in autoimmune connective tissue disease
10 patients and controls for an up to 7-year follow-up period.
11
12

13 Figure 3 Kaplan–Meier hazard curve for rotor cuff tear in autoimmune connective tissue disease
14 (ACTD) patients with or without nonsteroidal anti-inflammatory drug use and controls over a 7-year
15 follow-up period.
16
17

18
19 Figure 4 Kaplan–Meier hazard curve for rotor cuff tear in autoimmune connective tissue diseases
20 (ACTDs) patients with or without steroid use and controls over a 7-year follow-up period.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Demographic characteristics and comorbidities of autoimmune connective tissue disease (ACTD) patients and controls from 2004 to 2008.

| Baseline variable | ACTD cohort n = 5019 | | Control cohort n = 25095 | | P value | After propensity score adjusted P value |
|-----------------------------------|-------------------------|------|-----------------------------|------|---------|--|
| | No | (%) | No | (%) | | |
| Characteristics | | | | | | |
| Sex | | | | | | |
| Female | 3892 | 77.5 | 19460 | 77.5 | | |
| Male | 1127 | 22.5 | 5635 | 22.5 | | |
| Age (years) | | | | | | |
| 18–30 | 701 | 14.0 | 3505 | 14.0 | | |
| 31–40 | 816 | 16.3 | 4080 | 16.3 | | |
| 41–50 | 1042 | 20.8 | 5210 | 20.8 | | |
| 51–60 | 1029 | 20.5 | 5145 | 20.5 | | |
| 61–70 | 765 | 15.2 | 3825 | 15.2 | | |
| >70 | 666 | 13.3 | 3330 | 13.3 | | |
| Income | | | | | | |
| dependant | 1289 | 25.7 | 6523 | 26.0 | <0.001 | 0.478 |
| 1–25000 | 2217 | 44.2 | 12119 | 48.3 | | |
| 25001–50000 | 1095 | 21.8 | 4961 | 19.8 | | |
| >50000 | 418 | 8.3 | 1492 | 5.9 | | |
| Comorbid medical disorders | | | | | | |
| Fracture | | | | | | |
| Yes | 62 | 1.2 | 284 | 1.1 | 0.530 | 0.944 |
| No | 4957 | 98.8 | 24811 | 98.9 | | |
| DM | | | | | | |
| Yes | 562 | 11.2 | 2965 | 11.8 | 0.214 | 0.732 |
| No | 4457 | 88.8 | 22130 | 88.2 | | |
| Hypertension | | | | | | |
| Yes | 1300 | 25.9 | 6287 | 25.1 | 0.206 | 0.808 |
| No | 3719 | 74.1 | 18808 | 74.9 | | |
| Hyperlipidaemia | | | | | | |
| Yes | 891 | 17.8 | 3355 | 13.4 | <0.001 | 0.932 |
| No | 4128 | 82.2 | 21740 | 86.6 | | |
| Coronary heart disease | | | | | | |
| Yes | 660 | 13.2 | 2447 | 9.8 | <0.001 | 0.899 |
| No | 4359 | 86.8 | 22648 | 90.2 | | |
| Gout | | | | | | |
| Yes | 608 | 12.1 | 2278 | 9.1 | <0.001 | 0.901 |
| No | 4411 | 87.9 | 22817 | 90.9 | | |
| Thyroid | | | | | | |
| Yes | 416 | 8.3 | 1158 | 4.6 | <0.001 | 0.529 |
| No | 4603 | 91.7 | 23937 | 95.4 | | |
| Parkinson's disease | | | | | | |
| | | | | | 0.849 | 0.956 |

| | | | | |
|-----|------|------|-------|------|
| Yes | 74 | 1.5 | 379 | 1.5 |
| No | 4945 | 98.5 | 24716 | 98.5 |

For peer review only

Table 2. Crude and adjusted hazard ratios for RCT between the autoimmune connective tissue disease (ACTD) and non-ACTD cohorts during the 7-year follow-up period, starting from the index date of an ambulatory care visit (n = 30,114).

| Presence of RCT | Non-ACTD controls | ACTD patients |
|------------------------------------|-------------------|-------------------|
| 7-year follow-up period | | |
| Yes/Total | 37/25095 | 12/5019 |
| Person-years | 154275 | 24536 |
| Incidence per 100,000 person-years | 24 | 49 |
| Crude HR (95% CI) | 1.00 | 2.08* (1.08-4.02) |
| Adjusted HR ^a (95% CI) | 1.00 | 1.97* (1.01-3.82) |

Notes: ^a The propensity score was adjusted according to age, sex, income, diabetes mellitus, hypertension, hyperlipidaemia, coronary heart diseases, fracture, thyroid, gout and Parkinson's disease. *indicates $P < 0.05$

RCT: rotor cuff tear; HR: hazard ratio

Table 3. Crude and adjusted hazard ratios for rotor cuff tear in patients with autoimmune connective tissue diseases (ACTDs) with or without NSAID use and non-ACTD controls during the follow-up period starting from index of ambulatory care.

| Presence of RCT | Non-ACTD | Patients with ACTDs | |
|-----------------------------------|----------|--------------------------------|-----------------------|
| | | Without a history of NSAID use | History of NSAIDs use |
| 7-year follow-up period | | | |
| Yes/Total | 37/25095 | 7/3745 | 5/1274 |
| Crude HR (95% CI) | 1.00 | 1.61 (0.71–3.64) | 3.53** (1.38–9.01) |
| Adjusted HR ^a (95% CI) | 1.00 | 1.56 (0.69–3.53) | 3.13* (1.21–8.07) |

Notes: ^a The propensity score was adjusted according to age, sex, income, diabetes mellitus, hypertension, hyperlipidaemia, coronary heart diseases, fracture, thyroid, gout and Parkinson's disease. *indicates P < 0.05, **indicates P < 0.01

RCT: rotor cuff tear; HR: hazard ratio


Table 4. Crude and adjusted hazard ratios for rotor cuff tear in patients with autoimmune connective tissue diseases (ACTDs) with or without steroid use and non-ACTD controls during the follow-up period starting from index of ambulatory care.

| Presence of RCT | Non-ACTD | Patients with ACTD | |
|-----------------------------------|----------|----------------------------------|------------------------|
| | | Without a history of steroid use | History of steroid use |
| 7-year follow-up period | | | |
| Yes/Total | 37/25095 | 5/2452 | 7/2567 |
| Crude HR (95% CI) | 1.00 | 1.83 (0.71–4.67) | 2.32* (1.03–5.22) |
| Adjusted HR ^a (95% CI) | 1.00 | 1.70 (0.66–4.37) | 2.22 (0.98–5.03) |

Notes: ^a The propensity score was adjusted according to age, sex, income, diabetes mellitus, hypertension, hyperlipidaemia, coronary heart diseases, fracture, thyroid, gout and Parkinson's disease. *indicates $P < 0.05$.

RCT: rotor cuff tear; HR: hazard ratio

Figure 1



Autoimmune connective tissue diseases (ACTDs)

Figure1/Flowchart showing the study design

209x297mm (300 x 300 DPI)




Figure 2/Kaplan-Meier hazard curve for rotor cuff tear in autoimmune connective tissue disease patients and controls for an up to 7-year follow-up period.

318x232mm (72 x 72 DPI)




Figure 3/Kaplan–Meier hazard curve for rotor cuff tear in autoimmune connective tissue disease (ACTD) patients with or without nonsteroidal anti-inflammatory drug use and controls over a 7-year follow-up period.

318x233mm (72 x 72 DPI)




Figure 4/Kaplan–Meier hazard curve for rotator cuff tear in autoimmune connective tissue diseases (ACTDs) patients with or without steroid use and controls over a 7-year follow-up period.

322x235mm (72 x 72 DPI)

STROBE Statement

Checklist of items that should be included in reports of observational studies

| Section/Topic | Item No | Recommendation | Reported on Page No |
|---------------------------|---------|--|---------------------|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | 2 |
| | | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 3 |
| Introduction | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 4 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 5 |
| Methods | | | |
| Study design | 4 | Present key elements of study design early in the paper | 6 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 6-7 |
| Participants | 6 | (a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | 7-8 |
| | | <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls | |
| | | <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants | |
| Variables | 7 | (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed | 8 |
| | | <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case | |
| Data sources/measurement | 8* | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 8 |
| Bias | 9 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 7-8 |
| Study size | 10 | Describe any efforts to address potential sources of bias | 8 |
| Quantitative variables | 11 | Explain how the study size was arrived at | 8 |
| Statistical methods | 12 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 7-8 |
| | | (a) Describe all statistical methods, including those used to control for confounding | 9 |
| | | (b) Describe any methods used to examine subgroups and interactions | |
| | | (c) Explain how missing data were addressed | |
| | | (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed | |
| | | <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed | |
| | | <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy | |
| | | (e) Describe any sensitivity analyses | |

| Section/Topic | Item No | Recommendation | Reported on Page No |
|--------------------------|---------|--|---------------------|
| Results | | | |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 9-10 |
| | | (b) Give reasons for non-participation at each stage | 9-10 |
| | | (c) Consider use of a flow diagram | 9-10 |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 9-10 |
| | | (b) Indicate number of participants with missing data for each variable of interest | |
| | | (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) | |
| Outcome data | 15* | <i>Cohort study</i> —Report numbers of outcome events or summary measures over time | |
| | | <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure | 9-10 |
| | | <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures | |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 9-10 |
| | | (b) Report category boundaries when continuous variables were categorized | |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | |
| Discussion | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 10 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 14 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 10-14 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 14 |
| Other Information | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 15 |

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Autoimmune Connective Tissue Diseases Increase the Risk of Rotator Cuff Repair Surgery: a Population-Based Retrospective Cohort Study

| | |
|---------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2018-023848.R2 |
| Article Type: | Research |
| Date Submitted by the Author: | 20-Nov-2018 |
| Complete List of Authors: | Huang, ShihWei; Shuang Ho Hospital, Physical Medicine and Rehabilitation Lin, CheLi; Taipei Medical University Shuang Ho Hospital, Orthopedics Lin, LiFong; Shuang Ho Hospital, Physical Medicine and Rehabilitation Huang, ChiChang; Graduate Institute of Sports Science, National Taiwan Sport University Liou, Tsan-Hon; Shuang Ho Hospital, Physical Medicine and Rehabilitation Lin, Hui-Wen; Department of Mathematics, Soochow University |
| Primary Subject Heading: | Rheumatology |
| Secondary Subject Heading: | Rehabilitation medicine, Sports and exercise medicine |
| Keywords: | Rheumatology < INTERNAL MEDICINE, Orthopaedic sports trauma < ORTHOPAEDIC & TRAUMA SURGERY, Shoulder < ORTHOPAEDIC & TRAUMA SURGERY |
| | |

SCHOLARONE™
Manuscripts

Original Article

Autoimmune Connective Tissue Diseases Increase the Risk of Rotator Cuff Repair Surgery: A Population-Based Retrospective Cohort Study

Shih-Wei Huang^{1,2,3} MD, Che-Li Lin^{3,4} MD, Li-Fong Lin^{1,5} PhD, Chi-Chang Huang³ PhD, Tsan-Hon Liou^{1,2} MD, PhD, Hui-Wen Lin^{6,7*} PhD

Running title: ACTDs increase the risk of rotator cuff surgery

¹Department of Physical Medicine and Rehabilitation, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan

²Department of Physical Medicine and Rehabilitation, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

³Graduate Institute of Sports Science, National Taiwan Sport University, Taoyuan, Taiwan

⁴Department of Orthopedic Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan

⁵Institute of Gerontology and Health Management, Taipei Medical University, Taipei, Taiwan

⁶Department of Mathematics, Soochow University, Taipei, Taiwan

⁷Evidence-Based Medicine Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan

*Address for reprints:

Hui-Wen Lin, PhD

Department of Mathematics, Soochow University, 70 Linhsi Road, Shihlin, Taipei, Taiwan

Tel: 886-2-2881-9471 ext. 6701

Fax: 886-2-8861-1230

E-mail: linhw@tmu.edu.tw

Abstract

Objectives

Autoimmune connective tissue diseases (ACTDs) commonly involve the shoulder joint; however, clinical epidemiological studies investigating their association with tendons are scant. Rotator cuff (RC) tears can cause shoulder disability, and surgical intervention is usually required. The study investigated RC repair surgery risk in ACTD patients. The effect of anti-inflammatory medication on RC repair surgery risk was also investigated.

Methods

We conducted a retrospective cohort study with a 7-year longitudinal follow-up period. Patients with systemic lupus erythematosus, systemic sclerosis, sicca syndrome, dermatomyositis, and polymyositis diagnoses between 2004 and 2008 were enrolled. The control cohort comprised age- and sex-matched controls. The hazard ratio (HR) and adjusted HR (aHR) were estimated for the risk of RC surgery between ACTD and control cohorts after adjustment for confounders. Furthermore, the effects of steroid and nonsteroidal anti-inflammatory drug (NSAID) use on the HR and aHR of RC surgery risk were analysed.

Results

We enrolled 5,019 ACTD patients and 25,095 controls in the ACTD and control cohorts, respectively. RC surgery incidence was 49 and 24 per 100,000 person-years in the ACTD and control cohorts, respectively. In the ACTD cohort, the crude HR for RC surgery was 2.08 (95% confidence interval [CI], 1.08–4.02, $P < 0.05$), and the aHR was 1.97 (95% CI, 1.01–3.82, $P < 0.05$). The ACTD patients who used NSAIDs had an aHR of 3.13 (95% CI, 1.21–8.07, $P < 0.05$) compared with the controls, but the ACTD patients who used steroids did not have a significantly higher aHR than the controls.

Conclusions

ACTD patients had an increased risk of RC repair surgery. However, no difference was found in RC surgery risk when steroids were used compared with the control cohort. This could indicate that inflammation control may be a strategy for managing subsequent RC lesions.

Keywords: Autoimmune connective tissue diseases; rotator cuff surgery; risk factor; population-based study

Strengths and limitations of this study

- First large-scale, population-based study on the risk of rotator cuff (RC) lesions among patients with autoimmune connective tissue diseases (ACTDs).
- Detailed information of ACTD severity could not be presented.
- Although steroids can lower the risk of RC repair surgery among patients, our study did not analyse disease-modifying anti-rheumatic drugs, which might have influenced the inflammatory status of the study cohort.
- To enhance the accuracy of study outcomes, we only investigated the risk of RC lesions and the requirement of subsequent repair surgery; therefore, patients with minor tears or who did not require surgical intervention might have been missed.

Introduction

Autoimmune connective tissue diseases (ACTDs), such as systemic lupus erythematosus (SLE), systemic sclerosis, sicca syndrome, dermatomyositis, and polymyositis, are systemic autoimmune disorders that affect multiple organ systems and exhibit intermittent relapse and remission. Owing to the various organs involved in the chronic inflammatory process caused by autoantibody deposition and related inflammatory reactions, ACTD patients—particularly SLE patients—usually present heterogeneous clinical manifestations.[1] The musculoskeletal system is one of the organ systems that is often affected, and initial musculoskeletal symptoms are often similar to those of autoimmune diseases.[2] The severity of clinical musculoskeletal symptoms varies among individuals. SLE patients can present mild arthralgia without deformity or erosion, nonerosive deforming arthritis, or erosive symmetric polyarthritis. In addition, the musculoskeletal symptoms of these patients can include osteonecrosis, tendonitis, myositis, and tendon rupture.[3] However, few studies have investigated or emphasised lesions of the enthesis in SLE patients in connection with other ACTDs.[4, 5]

Rotator cuff (RC) tear or rupture is one of the most common causes of shoulder dysfunction. RC tears may be asymptomatic, or their clinical presentations can be pain accompanied by a limited range of movement. RC disorders are observed in 30%–70% of patients presenting with shoulder

1
2
3
4 pain, and the incidence of RC tears is 5%–40%.[6] Because RC tears can be asymptomatic, studies
5
6
7 have reported diverse prevalence rates of RC tears. An ultrasound screening study revealed that the
8
9
10 prevalence of RC tears was 20.47% among 1,366 shoulders with or without clinical symptoms, and
11
12
13 the prevalence increased with age.[7] Initially, RC tears can be treated using conventional methods
14
15
16 such as exercise or injections.[8] Patients with extensive RC tears experience limited shoulder
17
18
19 function when performing daily activities or working. Surgical repair is recommended to relieve
20
21
22 symptoms and restore function. RC repair surgery and subsequent possible complications can
23
24
25 increase patients' medical expenditure and the economic burden on health care systems.[9]
26
27
28
29
30
31

32
33 A cross-sectional study investigated hand tendons and revealed the predominance of
34
35
36 tenosynovitis or tendonitis.[10] Case reports have described the rupture of patellar and hand tendons
37
38
39 in SLE patients.[11, 12] Thus, we hypothesised that SLE patients have a relatively high risk of RC
40
41
42 repair surgery because of tendon lesions. In addition, case reports of tendon rupture have mentioned
43
44
45 other ACTDs such as dermatomyositis.[13] A massive RC tear can cause shoulder disability and
46
47
48 surgical intervention is usually required. However, sufficient epidemiological research has not been
49
50
51 conducted to prove that SLE and other ACTDs are risk factors for RC tears requiring repair surgery.
52
53
54 Thus, we hypothesised that ACTD patients have a higher risk of RC lesions that require repair
55
56
57 surgery and conducted this longitudinal, retrospective cohort study to investigate this risk. In addition,
58
59
60

1
2
3
4 we investigated the effect of anti-inflammatory medication on the RC repair surgery risk for ACTD
5
6
7 patients.
8
9

10 11 12 **Methods**

13 14 15 **Study design**

16
17
18
19 Using a health care database, this longitudinal retrospective cohort study analysed the risk of RC
20
21
22 repair surgery for ATCD patients. We included patients who had been diagnosed with ACTDs
23
24
25 between 1 January 2004 and 31 December 2008. Their data were obtained from the Taiwan
26
27
28 Longitudinal Health Insurance Database 2005 (LHID2005), part of Taiwan's National Health
29
30
31 Insurance Research Database (NHIRD). A control cohort consisting of five age- and sex-matched
32
33
34 non-ACTD controls per ACTD patient was obtained using the same database. We retrieved data
35
36
37 from the database since 2004 with a follow-up period of 2–7 years or until the end of 2010. The
38
39
40 follow-up period ended when the patients or controls received RC repair surgery. To ensure
41
42
43 patient privacy, their names and identity numbers were replaced by numbers and letters from the
44
45
46 English alphabet codes that are used for identifying patient data in the NHIRD. Because the linked
47
48
49 identity data were removed, patients' data could not be identified, and thus, the requirement for
50
51
52 informed consent was waived. This study was approved by the Institutional Review Board of the
53
54
55 University of Taipei (UT-IRB No.: IRB-2018-07).
56
57
58
59
60

1
2
3
4
5
6
7 Brief background of Taiwan's National Health Insurance (NHI) system, NHIRD, and LHID2005
8
9

10 Taiwan's NHI system is a form of social insurance that covers more than 96% of the population
11
12 of Taiwan.[14, 15] The NHI programme covers almost all medical services, such as outpatient visits,
13
14 admission services, and emergency hospitalisations. Diagnoses made using International
15
16 Classification of Diseases Ninth Revision, Clinical Modification (ICD-9-CM) codes, medical
17
18 prescriptions, procedures, and surgeries are recorded in the NHIRD. As previously mentioned, the
19
20 data used in this study were obtained from the Taiwan LHID2005, which contains the data of
21
22 1,000,000 beneficiaries randomly sampled from the Registry for Beneficiaries of the NHIRD. For
23
24 research purposes, the National Health Research Institutes of Taiwan collects and maintains
25
26 registration files and original claims data from the NHI administration and then releases them
27
28 publicly through the NHIRD.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 Inclusion and exclusion criteria 46 47

48 The study cohort included ACTD patients diagnosed with SLE (ICD-9-CM code 710.0),
49
50 systemic sclerosis (ICD-9-CM code 710.1), sicca syndrome (ICD-9-CM code 710.2),
51
52 dermatomyositis (ICD-9-CM code 710.3), and polymyositis (ICD-9-CM code 710.4) by using the
53
54 American College of Rheumatology criteria between 1 January 2004 and 31 December 2008. To
55
56
57
58
59
60

1
2
3
4 ensure high accuracy of the ACTD diagnoses, this study only selected patients diagnosed with
5
6
7 ACTDs at least twice consistently, according to ICD-9-CM codes, in outpatient clinics or those who
8
9
10 had a primary diagnosis of ACTDs during hospitalisation within 1 year and were older than 20 years.
11
12
13 ACTD patients who had undergone RC repair surgery before 2004, had missing data, or had died
14
15
16 during the follow-up period were excluded from the study. Finally, 5,019 ACTD patients were
17
18
19
20 enrolled into the study cohort (Figure 1).
21
22
23
24
25

26 Confounders and propensity score adjustment

27
28
29 In addition to the demographic variables of age and sex, economic status and comorbidities such
30
31
32 as diabetes mellitus (ICD-9-CM codes 250 and 251), hypertension (ICD-9-CM codes 401–405),
33
34
35 hyperlipidaemia (ICD-9-CM codes 272.0–272.4), coronary heart disease, gout, nonsteroidal anti-
36
37
38 inflammatory drugs (NSAIDs), steroid use (defined as 3 months of consecutive use), and fractures
39
40
41 were analysed in this study. Regarding thyroid diseases and RC tear risk, we also analysed thyroid
42
43
44 disorders as a morbidity.[16] Furthermore, comorbidities were determined at the specific time point
45
46
47 that the patients were enrolled into the study and not changed during the follow-up period. To
48
49
50
51 minimise bias in data selection from the study database, we used propensity scores adjusted for
52
53
54 comorbidities and income, as shown in Table 1.
55
56
57
58
59
60

Outcome identification

We used the first RC repair surgery with the relevant application codes (64121B and 64122B) as the study endpoint from the same database. All participants were followed from the index date to the endpoint or until 31 December 2010, whichever was earlier, and the final-date observations were censored observations.

Statistical analysis

Demographic characteristics and comorbidities were analysed using Pearson's chi-squared test. We calculated the incidence of ACTDs and compared the risk of RC repair surgery between the two cohorts by using the Cox model after propensity score adjustment. Furthermore, we compared the risk of repair surgery in the ACTD patients who did or did not receive medication (NSAIDs and steroids) with that in the non-ACTD controls. To clarify the association between medication and RC tears, Kaplan–Meier hazard curves were plotted for RC tears in the ACTD patients who did or did not receive NSAIDs and the controls as well as in the ACTD patients who did or did not receive steroids and the controls for a 7-year follow-up period. All data analyses were performed using Stata (Version 11) and SAS (Version 9.1.3; SAS Institute, Cary, NC, USA). A value of $P < 0.05$ was considered statistically significant.

Patient involvement

1
2
3
4 No patients were involved in developing the hypothesis, specific aims, or the research questions,
5
6
7 nor were they involved in developing plans for the design or implementation of the study. No
8
9
10 patients were involved in the interpretation of the study results or writing of the manuscript. No plans
11
12
13 exist to disseminate the research results to the study participants or the relevant patient community.
14
15

16 17 **Results** 18

19
20 In total, 5,019 ACTD patients were in the study cohort and 25,095 patients were in the control
21
22 cohort. Women constituted 77.5% of each cohort and no statistical differences existed in age or sex.
23
24 The prevalence of the comorbidities hyperlipidaemia (17.8%), coronary heart disease (13.2%), gout
25
26 (12.1%), and thyroid disorders (8.3%) were higher in the ACTD cohort than in the control cohort
27
28 (Table 1). The incidence of RC repair surgery was 49.0 and 24.0 per 100,000 person-years in the
29
30 ACTD and control cohorts, respectively. In the ACTD cohort, the crude hazard ratio (HR) of RC
31
32 repair surgery was 2.08 (95% confidence interval [CI], 1.08–4.02, $P < 0.05$), and the adjusted HR
33
34 (aHR) was 1.97 (95% CI, 1.01–3.82, $P < 0.05$) (Table 2). Figure 2 presents the Kaplan–Meier hazard
35
36 curves for the risk of RC repair surgery in the ACTD and control cohorts during the 7-year follow-up
37
38 period. A comparison of the patients who did and did not use NSAIDs (separately) with the controls
39
40 revealed that the ACTD patients with records of NSAID use had a higher risk of RC repair surgery
41
42 (aHR = 3.13, 95% CI, 1.21–8.07, $P < 0.05$) than did the ACTD patients without records of NSAID
43
44 use (Table 3). Figure 3 presents the Kaplan–Meier hazard curves for the risk of RC repair surgery in
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 the ACTD patients who used NSAIDs, the ACTD patients who did not use NSAIDs, and the controls
5
6
7 during the 7-year follow-up period. Further analysis of the association between steroid use and the
8
9
10 risk of RC repair surgery showed that the crude HR was 2.32 (95% CI, 1.03–5.22, P = 0.042) among
11
12
13 the ACTD patients who used steroids. However, the risk of RC surgery in the ACTD patients was
14
15
16 not significantly higher than that in the controls in terms of adjusted HR (aHR= 2.22, 95% CI, 0.98–
17
18
19 5.03, P = 0.067) when using steroids (Table 4). Figure 4 represents the trend of the risk of RC repair
20
21
22 surgery; the risk increased among the ACTD patients who used steroids, but it was not significant
23
24
25 during the 7 year follow-up period.
26
27
28
29
30
31
32
33
34
35

36 Discussion

37
38
39 Although case reports have described spontaneous ruptures in the supraspinatus tendon, patellar
40
41
42 tendon, and hand flexor tendon,[11-13, 17] no relevant epidemiological study has investigated the
43
44
45 risk of RC lesions among ACTD patients until now. In our population-based cohort study, the ACTD
46
47
48 patients had a higher risk of RC repair surgery than the controls. This finding indicates that in
49
50
51 addition to the joints, the periarticular soft tissue is affected in ACTDs. During the 7-year
52
53
54 longitudinal follow-up period, the number of RC repair surgery events increased with disease
55
56
57 progression. To improve quality of life of ACTD patients, prevent negative effects of RC injuries,
58
59
60

1
2
3
4 and develop an effective prevention strategy, identifying the possible mechanism of ACTD
5
6
7 pathogenesis is crucial.
8
9

10
11
12
13
14 The factors involved in RC injury pathogenesis can typically be classified into extrinsic and
15
16
17 intrinsic factors.[18] For ACTD patients, we supposed that intrinsic pathogenic aetiologies play a
18
19
20 crucial role in increasing the risk of RC injuries and the subsequent requirement of repair surgery.
21
22
23 ACTD patients exhibit the characteristics of systemic inflammatory processes, and subsequently,
24
25
26 inflammation reactions affect the RC tendon. Subclinical inflammation persists in these ACTD
27
28
29 patients even after their clinical symptoms are under control. Subclinical chronic inflammation can
30
31
32 disrupt the tendon healing and remodelling process, which can lead to weakening of the tendon,
33
34
35 thereby increasing the risk of subsequent tendon rupture. Previous case reports have found
36
37
38 perivascular mononuclear cell infiltration in the ruptured tendon, which was caused by the ACTD
39
40
41 inflammatory process.[19, 20] The inflammatory phenomenon can also be detected using ultrasound
42
43
44 techniques. A study reported that 49.4% of ultrasound abnormalities were tenosynovitis.[21] In
45
46
47 addition to tenosynovitis, ultrasound detected chronic tendinopathy, which led to degeneration of the
48
49
50 tendon; the weakened structure was highly vulnerable to injuries. These intrinsic aetiologies of
51
52
53 tendon inflammation and subsequent tendon degeneration can lead to a high risk of RC injuries and
54
55
56 the subsequent requirement of repair surgery among ACTD patients.
57
58
59
60

1
2
3
4
5
6
7 ACTDs represent complicated chronic inflammatory autoimmune diseases with no curative
8
9
10 treatment options. To arrest the progression of autoimmune diseases, systemic steroids are often used
11
12
13 and combined with nonsteroidal medication to control flare-up episodes.[22] Corticosteroids can
14
15
16 accelerate the progression of weakness by inhibiting collagen synthesis and impairing blood
17
18
19 supply.[23] Corticosteroids inhibit collagen synthesis and may also impair blood supply, thereby
20
21
22 weakening the tendons.[5] A critical zone near the insertion of the supraspinatus has been described
23
24
25 using microangiographic evidence of an area of hypovascularity in the tendon close to its humeral
26
27
28 insertion. Relative ischaemia in this zone is reported to mimic tendon degeneration.[6] In addition,
29
30
31 studies have mentioned that chronic synovitis, tenosynovitis, and long-term steroid use can lead to
32
33
34 degeneration, thereby increasing the vulnerability of the flexor tendon in ACTD patients.[24, 25]
35
36
37 However, our study revealed that steroid use in all patients and controls did not significantly increase
38
39
40 the risk of RC repair surgery. Relevant studies have shown that inflammatory changes occur at the
41
42
43 site of tendon rupture; these changes have been observed in ACTD patients.[19, 26] Although
44
45
46 steroids can lead to tendon degeneration, inflammatory processes can be arrested by steroid
47
48
49 administration. We hypothesised that the net effect of steroid use can increase the risk of RC repair
50
51
52 surgery; however, this effect was not significant in the ACTD patients. Furthermore, the ACTD-
53
54
55 induced chronic inflammatory process and related degeneration can accelerate the weakening of RC
56
57
58
59
60

1
2
3
4 with ageing.
5
6
7
8
9

10 Our study revealed that ACTDs are a risk factor for RC repair surgery. We hypothesised that the
11 possible mechanism underlying this association was chronic inflammation and tendon degeneration,
12
13 which damage and weaken the RC's structure. The strength of this study is its large sample size and
14
15 data analysis. Moreover, it is the first epidemiological study to investigate the association between
16
17 ACTDs and the risk of RC lesions and surgery. Nevertheless, this study has several limitations that
18
19 must be addressed. First, the diagnosis of ACTDs and comorbidities were defined using ICD codes
20
21 from the database; hence, the accuracy should be examined. For accurate payments, the Bureau of
22
23 NHI reviews medical records regularly. Patients with SLE, dermatomyositis, and polymyositis in
24
25 Taiwan can apply for catastrophic illness registration cards, and copayment is free for SLE-related
26
27 medical problems. In addition to the accuracy of ACTD diagnosis, the definite onset duration of
28
29 ACTDs could not be obtained from the database, and the diversity of follow-up periods for the study
30
31 cohort must be addressed. Second, laboratory data of the inflammatory status and severity of ACTDs
32
33 could not be obtained from the database. Moreover, the severity and status of ACTDs could not be
34
35 categorised in the database and we could not identify which statuses of ACTD patients were at a high
36
37 risk of tendon lesions. Furthermore, disease-modifying anti-rheumatic drugs (DMARDs), which
38
39 could influence the severity of ACTDs, were not analysed because of the complexity of use from this
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 database. Further studies on DMARDs' effect on RC lesions are required to investigate separate
5
6
7 diseases among ACTDs. Third, extrinsic factors affecting RC injuries include repeated impingement
8
9
10 and overuse during work and daily living activities. These factors can increase the risk of repair
11
12
13 surgery. However, data on work status, daily activities, body weight, alcohol consumption, and
14
15
16 smoking are not available in the database; although a large sample size was obtained, these
17
18
19 confounders could not be excluded completely from this study. Finally, for higher accuracy, we only
20
21
22 investigated the risk of RC lesions and requirement of subsequent repair surgery; therefore, patients
23
24
25 with minor tears or those who did not require surgical intervention might have been missed. Despite
26
27
28 the limited information available on the types of RC lesion, our population-based study provided
29
30
31 crucial information on the high risk of RC surgery among ACTD patients.
32
33
34
35
36
37
38

39 **Conclusion**

40
41
42 The results of this 7-year longitudinal population-based retrospective cohort study showed that
43
44
45 ACTD patients had a 1.97-fold higher risk of RC repair surgery than the controls. Additional studies
46
47
48 on inflammation severity in ACTDs and the effects of ACTD-related medication on the risk of RC
49
50
51 lesions are recommended.
52
53
54
55
56
57
58
59
60

1
2
3
4
5 Acknowledgments: None.
6
7
8
9

10 Contributors: H-SW participated in the study design, conducted the data analysis, drafted the initial
11 manuscript, and approved the final manuscript as submitted. L-CL conducted the data analysis,
12 drafted the manuscript, and approved the final manuscript as submitted. L-LF contributed to the
13 study design, reviewed and revised the manuscript, and approved the final manuscript as submitted.
14 H-CC reviewed and revised the manuscript and approved the final manuscript as submitted. L-TH
15 participated in the study design, reviewed and revised the manuscript, and approved the final
16 manuscript as submitted. RE designed and conceptualised the study and approved the final
17 manuscript as submitted. L-HW participated in the study design, conducted the data analysis, revised
18 the manuscript, and approved the final manuscript as submitted.
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 Funding: None.
34

35 Competing interests: None to declare.
36

37 Ethics approval: Institutional Review Board of the University of Taipei (UT-IRB No.: IRB-2018-07).
38

39 Data sharing statement: From Hui-Wen Lin, linhw@tmu.edu.tw
40
41
42
43
44

45 Provenance and peer review: Not commissioned; externally peer reviewed.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference

1. Tsokos GC. Systemic lupus erythematosus. *The New England journal of medicine* 2011;**365**(22):2110-21 doi: 10.1056/NEJMra1100359[published Online First: Epub Date]].
2. Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. *Clinics in dermatology* 2006;**24**(5):348-62 doi: 10.1016/j.clindermatol.2006.07.014[published Online First: Epub Date]].
3. Zoma A. Musculoskeletal involvement in systemic lupus erythematosus. *Lupus* 2004;**13**(11):851-3 doi: 10.1191/0961203303lu2021oa[published Online First: Epub Date]].
4. Gutierrez M, Filippucci E, De Angelis R, et al. Subclinical enthesal involvement in patients with psoriasis: an ultrasound study. *Seminars in arthritis and rheumatism* 2011;**40**(5):407-12 doi: 10.1016/j.semarthrit.2010.05.009[published Online First: Epub Date]].
5. Grossman JM. Lupus arthritis. *Best practice & research. Clinical rheumatology* 2009;**23**(4):495-506 doi: 10.1016/j.berh.2009.04.003[published Online First: Epub Date]].
6. Oliva F, Piccirilli E, Bossa M, et al. I.S.Mu.L.T - Rotator Cuff Tears Guidelines. *Muscles, ligaments and tendons journal* 2015;**5**(4):227-63 doi: 10.11138/mltj/2015.5.4.227[published Online First: Epub Date]].
7. Yamamoto A, Takagishi K, Osawa T, et al. Prevalence and risk factors of a rotator cuff tear in the general population. *Journal of shoulder and elbow surgery* 2010;**19**(1):116-20 doi: 10.1016/j.jse.2009.04.006[published Online First: Epub Date]].
8. Abdul-Wahab TA, Betancourt JP, Hassan F, et al. Initial treatment of complete rotator cuff tear and transition to surgical treatment: systematic review of the evidence. *Muscles, ligaments and tendons journal* 2016;**6**(1):35-47 doi: 10.11138/mltj/2016.6.1.035[published Online First: Epub Date]].
9. Colvin AC, Egorova N, Harrison AK, et al. National trends in rotator cuff repair. *The Journal of bone and joint surgery. American volume* 2012;**94**(3):227-33 doi: 10.2106/JBJS.J.00739[published Online First: Epub Date]].
10. Ogura T, Hirata A, Hayashi N, et al. Comparison of ultrasonographic joint and tendon findings in hands between early, treatment-naive patients with systemic lupus erythematosus and rheumatoid arthritis. *Lupus* 2017;**26**(7):707-14 doi: 10.1177/0961203316676375[published Online First: Epub Date]].
11. Albayrak I, Kucuk A, Arslan S, et al. Spontaneous patellar tendon rupture in a case followed up for diagnosis of systemic lupus erythematosus. *European journal of rheumatology* 2014;**1**(4):159-60 doi: 10.5152/eurjrheumatol.2014.140044[published Online First: Epub Date]].
12. Hosokawa T, Oda R, Toyama S, et al. Spontaneous flexor tendon rupture due to an insufficiency fracture of the hamate hook in a patient with systemic lupus erythematosus: A case report.

- 1
2
3 International journal of surgery case reports 2016;**27**:63-65 doi:
4 10.1016/j.ijscr.2016.06.052[published Online First: Epub Date]].
5
6
7 13. Nakamura S, Nakagawa J. Recurrent extensor tendon rupture in adult-onset dermatomyositis: a
8 case report. *Clinical rheumatology* 2005;**24**(4):409-10 doi: 10.1007/s10067-004-1050-
9 0[published Online First: Epub Date]].
10
11 14. Cheng TM. Taiwan's new national health insurance program: genesis and experience so far.
12 *Health affairs* 2003;**22**(3):61-76 doi: 10.1377/hlthaff.22.3.61[published Online First: Epub
13 Date]].
14
15 15. Cheng SH, Chiang TL. The effect of universal health insurance on health care utilization in
16 Taiwan. Results from a natural experiment. *Jama* 1997;**278**(2):89-93
17
18 16. Oliva F, Osti L, Padulo J, et al. Epidemiology of the rotator cuff tears: a new incidence related to
19 thyroid disease. *Muscles Ligaments Tendons J* 2014;**4**(3):309-14
20
21 17. Prabu VN, Agrawal S, Kishore JK, et al. Supraspinatus tendon rupture in lupus: a rarity. *Lupus*
22 2009;**18**(11):1026-7 doi: 10.1177/0961203309103099[published Online First: Epub Date]].
23
24 18. Via AG, De Cupis M, Spoliti M, et al. Clinical and biological aspects of rotator cuff tears.
25 *Muscles, ligaments and tendons journal* 2013;**3**(2):70-9 doi:
26 10.11138/mltj/2013.3.2.070[published Online First: Epub Date]].
27
28 19. Potasman I, Bassan HM. Multiple tendon rupture in systemic lupus erythematosus: case report
29 and review of the literature. *Annals of the rheumatic diseases* 1984;**43**(2):347-9
30
31 20. Lu M, Johar S, Veenema K, et al. Patellar tendon rupture with underlying systemic lupus
32 erythematosus: a case report. *The Journal of emergency medicine* 2012;**43**(1):e35-8 doi:
33 10.1016/j.jemermed.2009.08.054[published Online First: Epub Date]].
34
35 21. Di Matteo A, De Angelis R, Cipolletta E, et al. Systemic lupus erythematosus arthropathy: the
36 sonographic perspective. *Lupus* 2017;961203317747716 doi:
37 10.1177/0961203317747716[published Online First: Epub Date]].
38
39 22. Thamer M, Hernan MA, Zhang Y, et al. Prednisone, lupus activity, and permanent organ
40 damage. *The Journal of rheumatology* 2009;**36**(3):560-4 doi:
41 10.3899/jrheum.080828[published Online First: Epub Date]].
42
43 23. Halpern AA, Horowitz BG, Nagel DA. Tendon ruptures associated with corticosteroid therapy.
44 *The Western journal of medicine* 1977;**127**(5):378-82
45
46 24. Zayat AS, Md Yusof MY, Wakefield RJ, et al. The role of ultrasound in assessing
47 musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review.
48 *Rheumatology* 2016;**55**(3):485-94 doi: 10.1093/rheumatology/kev343[published Online First:
49 Epub Date]].
50
51 25. Alves EM, Macieira JC, Borba E, et al. Spontaneous tendon rupture in systemic lupus
52 erythematosus: association with Jaccoud's arthropathy. *Lupus* 2010;**19**(3):247-54 doi:
53
54
55
56
57
58
59
60

1
2
3 10.1177/0961203309351729[published Online First: Epub Date].
4

5 26. Furie RA, Chartash EK. Tendon rupture in systemic lupus erythematosus. *Seminars in arthritis*
6 *and rheumatism* 1988;**18**(2):127-33
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 **Figure Legends**

6 **Figure 1. Flowchart showing the study design**

8
9
10 **Figure 2. Kaplan–Meier hazard curve for rotor cuff tears in patients with autoimmune connective**
11 **tissue diseases and controls over a 7-year follow-up period**

12
13
14 **Figure 3. Kaplan–Meier hazard curve for rotor cuff tears in patients with autoimmune connective**
15 **tissue diseases with or without nonsteroidal anti-inflammatory drug use and controls over a 7-year**
16 **follow-up period**

17
18
19
20
21 **Figure 4. Kaplan–Meier hazard curve for rotor cuff tears in patients with autoimmune connective**
22 **tissue diseases with or without steroid use and controls over a 7-year follow-up period**

Table 1. Demographic characteristics and comorbidities of autoimmune connective tissue disease (ACTD) patients and controls from 2004 to 2008

| Baseline variable | ACTD cohort n = 5019 | | Control cohort n = 25095 | | P value | After propensity score adjustment P value |
|-----------------------------------|-------------------------|------|-----------------------------|------|---------|---|
| | No | (%) | No | (%) | | |
| Characteristics | | | | | | |
| Sex | | | | | | |
| Female | 3,892 | 77.5 | 19,460 | 77.5 | | |
| Male | 1,127 | 22.5 | 5,635 | 22.5 | | |
| Age (years) | | | | | | |
| 18–30 | 701 | 14.0 | 3,505 | 14.0 | | |
| 31–40 | 816 | 16.3 | 4,080 | 16.3 | | |
| 41–50 | 1,042 | 20.8 | 5,210 | 20.8 | | |
| 51–60 | 1,029 | 20.5 | 5,145 | 20.5 | | |
| 61–70 | 765 | 15.2 | 3,825 | 15.2 | | |
| >70 | 666 | 13.3 | 3,330 | 13.3 | | |
| Income | | | | | | |
| dependant | 1,289 | 25.7 | 6,523 | 26.0 | <0.001 | 0.478 |
| 1–25000 | 2,217 | 44.2 | 12,119 | 48.3 | | |
| 25001–50000 | 1,095 | 21.8 | 4,961 | 19.8 | | |
| >50000 | 418 | 8.3 | 1,492 | 5.9 | | |
| Comorbid medical disorders | | | | | | |
| Fracture | | | | | | |
| Yes | 62 | 1.2 | 284 | 1.1 | 0.530 | 0.944 |
| No | 4,957 | 98.8 | 24,811 | 98.9 | | |
| DM | | | | | | |
| Yes | 562 | 11.2 | 2,965 | 11.8 | 0.214 | 0.732 |
| No | 4,457 | 88.8 | 22,130 | 88.2 | | |
| Hypertension | | | | | | |
| Yes | 1,300 | 25.9 | 6,287 | 25.1 | 0.206 | 0.808 |
| No | 3,719 | 74.1 | 18,808 | 74.9 | | |
| Hyperlipidaemia | | | | | | |
| Yes | 891 | 17.8 | 3,355 | 13.4 | <0.001 | 0.932 |
| No | 4,128 | 82.2 | 21,740 | 86.6 | | |
| Coronary heart disease | | | | | | |
| Yes | 660 | 13.2 | 2,447 | 9.8 | <0.001 | 0.899 |
| No | 4,359 | 86.8 | 22,648 | 90.2 | | |
| Gout | | | | | | |
| Yes | 608 | 12.1 | 2,278 | 9.1 | <0.001 | 0.901 |
| No | 4,411 | 87.9 | 22,817 | 90.9 | | |
| Thyroid | | | | | | |
| Yes | 416 | 8.3 | 1,158 | 4.6 | <0.001 | 0.529 |
| No | 4,603 | 91.7 | 23,937 | 95.4 | | |
| Parkinson's disease | | | | | | |
| | | | | | 0.849 | 0.956 |

| | | | | |
|-----|-------|------|--------|------|
| Yes | 74 | 1.5 | 379 | 1.5 |
| No | 4,945 | 98.5 | 24,716 | 98.5 |

Table 2. Crude and adjusted hazard ratios for rotor cuff tear (RCT) between the autoimmune connective tissue disease (ACTD) and non-ACTD cohorts during the 7-year follow-up period, starting from the index date of an ambulatory care visit (n = 30,114)

| Presence of RCT | Non-ACTD controls | Patients with ACTDs |
|------------------------------------|-------------------|---------------------|
| 7-year follow-up period | | |
| Yes/Total | 37/25,095 | 12/5,019 |
| Person-years | 154,275 | 24,536 |
| Incidence per 100,000 person-years | 24 | 49 |
| Crude HR (95% CI) | 1.00 | 2.08* (1.08–4.02) |
| Adjusted HR ^a (95% CI) | 1.00 | 1.97* (1.01–3.82) |

Notes: ^aThe propensity score was adjusted according to age, sex, income, diabetes mellitus, hypertension, hyperlipidaemia, coronary heart disease, fracture, thyroid, gout, and Parkinson's disease. *indicates $P < 0.05$

RCT: rotor cuff tear; HR: hazard ratio

Table 3. Crude and adjusted hazard ratios for rotor cuff tear (RCT) in patients with autoimmune connective tissue diseases (ACTDs) with or without NSAID use and non-ACTD controls during the follow-up period, starting from the index date of an ambulatory care visit

| Presence of RCT | Non-ACTD | Patients with ACTDs | |
|-----------------------------------|-----------|--------------------------------|----------------------|
| | | Without a history of NSAID use | History of NSAID use |
| 7-year follow-up period | | | |
| Yes/Total | 37/25,095 | 7/3,745 | 5/1,274 |
| Crude HR (95% CI) | 1.00 | 1.61 (0.71–3.64) | 3.53** (1.38–9.01) |
| Adjusted HR ^a (95% CI) | 1.00 | 1.56 (0.69–3.53) | 3.13* (1.21–8.07) |

Notes: ^aThe propensity score was adjusted according to age, sex, income, diabetes mellitus, hypertension, hyperlipidaemia, coronary heart disease, fracture, thyroid, gout, and Parkinson's disease. *indicates P < 0.05, **indicates P < 0.01

RCT: rotor cuff tear; HR: hazard ratio


Table 4. Crude and adjusted hazard ratios for rotor cuff tear (RCT) in patients with autoimmune connective tissue diseases (ACTDs) with or without steroid use and non-ACTD controls during the follow-up period, starting from the index date of an ambulatory care visit

| Presence of RCT | Non-ACTD | Patients with ACTDs | |
|-----------------------------------|-----------|----------------------------------|------------------------|
| | | Without a history of steroid use | History of steroid use |
| 7-year follow-up period | | | |
| Yes/Total | 37/25,095 | 5/2,452 | 7/2,567 |
| Crude HR (95% CI) | 1.00 | 1.83 (0.71–4.67) | 2.32* (1.03–5.22) |
| Adjusted HR ^a (95% CI) | 1.00 | 1.70 (0.66–4.37) | 2.22 (0.98–5.03) |

Notes: ^aThe propensity score was adjusted according to age, sex, income, diabetes mellitus, hypertension, hyperlipidaemia, coronary heart disease, fracture, thyroid, gout, and Parkinson's disease. *indicates P < 0.05.

RCT: rotor cuff tear; HR: hazard ratio

Figure 1



Autoimmune connective tissue diseases (ACTDs)

Figure1/Flowchart showing the study design

209x297mm (300 x 300 DPI)




Figure 2/Kaplan–Meier hazard curve for rotator cuff tears in patients with autoimmune connective tissue diseases and controls over a 7-year follow-up period

99x70mm (300 x 300 DPI)




Figure 3/Kaplan–Meier hazard curve for rotor cuff tears in patients with autoimmune connective tissue diseases with or without nonsteroidal anti-inflammatory drug use and controls over a 7-year follow-up period

99x72mm (300 x 300 DPI)




Figure 4/Kaplan–Meier hazard curve for rotor cuff tears in patients with autoimmune connective tissue diseases with or without steroid use and controls over a 7-year follow-up period

99x71mm (300 x 300 DPI)

STROBE Statement

Checklist of items that should be included in reports of observational studies

| Section/Topic | Item No | Recommendation | Reported on Page No |
|---------------------------|---------|--|---------------------|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | 2 |
| | | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 3 |
| Introduction | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 4 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 5 |
| Methods | | | |
| Study design | 4 | Present key elements of study design early in the paper | 6 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 6-7 |
| Participants | 6 | (a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | 7-8 |
| | | <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls | |
| | | <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants | |
| Variables | 7 | (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed | 8 |
| | | <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case | |
| Data sources/measurement | 8* | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 8 |
| Bias | 9 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 7-8 |
| Study size | 10 | Describe any efforts to address potential sources of bias | 8 |
| Quantitative variables | 11 | Explain how the study size was arrived at | 8 |
| Statistical methods | 12 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 7-8 |
| | | (a) Describe all statistical methods, including those used to control for confounding | 9 |
| | | (b) Describe any methods used to examine subgroups and interactions | |
| | | (c) Explain how missing data were addressed | |
| | | (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed | |
| | | <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed | |
| | | <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy | |
| | | (e) Describe any sensitivity analyses | |

| Section/Topic | Item No | Recommendation | Reported on Page No |
|--------------------------|---------|--|---------------------|
| Results | | | |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 9-10 |
| | | (b) Give reasons for non-participation at each stage | 9-10 |
| | | (c) Consider use of a flow diagram | 9-10 |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 9-10 |
| | | (b) Indicate number of participants with missing data for each variable of interest | |
| | | (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) | |
| Outcome data | 15* | <i>Cohort study</i> —Report numbers of outcome events or summary measures over time | |
| | | <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure | 9-10 |
| | | <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures | |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 9-10 |
| | | (b) Report category boundaries when continuous variables were categorized | |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | |
| Discussion | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 10 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 14 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 10-14 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 14 |
| Other Information | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 15 |

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.